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INTRODUCTION 
 
 
Regional anaesthesia is the preferred technique for most of the lower 
abdomen and lower limb surgeries. It allows the patient to remain awake, 
minimizes or completely avoids the problem associated with airway 
management. With spinal anaesthesia, the technique is simple to perform, 
the onset of anaesthesia is more rapid, avoids poly pharmacy and also 
provides post-operative analgesia. 
 
Spinal anaesthesia with cocaine was initially produced inadvertently 
by Leonard J Corning in 1885 and first used deliberately by August Bier in 
18981. For decades lignocaine had been the local anaesthetic of choice for 
spinal anaesthesia. Its advantages are rapid onset of action and good motor 
block manifested as good muscle relaxation. Its use is limited by its short 
duration of action and has been implicated in transient neurologic 
symptoms and caudaequina syndrome following intrathecal injection.2,3 
 
Bupivacaine is three to four times more potent than lignocaine4 and 
has longer duration of action. Its disadvantages are slow onset of action and 
decreased motor block.Hyperbaric bupivacaine 0.5% is extensively used in 
India for spinal anaesthesia. Though the duration of action of bupivacaine is 
prolonged, it does not produce prolonged post-operative analgesia. Hence 
an adjuvant is required for producing prolonged post-operative analgesia. 
The discovery of opioid receptors and endorphins in spinal and 
2 
 
supraspinalregions soon led to the use of spinal opiates. Morphine was the 
first opioid administered intrathecally to augment neuraxial blocks.5 Opioid 
analgesic drugs produce intense, prolonged analgesic action without any 
gross autonomic changes, loss of motor power or impairment of sensation 
other than pain when injected into subarachnoid or epidural space.5 
Morphine can produce serious side effects like delayed and 
unpredictable respiratory depression, post-operative nausea and vomiting, 
pruritus and urinary retention.7,8 
Recently α-2 adrenoreceptor agonists have been used as adjuvants to 
local anaesthetic agents because of their sedative, analgesic and 
haemodynamic stabilizing effect. They have been found to prolong the 
duration of spinal block following intrathecal administration.9 
Clonidine, an α-2 adrenergic agonist, has a variety of different actions. 
Oral clonidine was used to prolong spinal anaesthesia. Hypotension was 
more pronounced after oral than intrathecal clonidine.10 Addition of 
intrathecal clonidine to bupivacaine prolongs analgesia and decreases 
morphine consumption postoperatively more than oral clonidine. Clonidine 
has antihypertensive properties and the ability to potentiate the effects of 
local anaesthetics.11 
Clonidine has been shown to result in prolongation of the sensory 
blockade and reduction in the volume or concentration of local anesthetic 
required to produce post-operative analgesia.12 Clonidine also has the 
3 
 
ability to prolong the motor blockade produced by bupivacaine. Large doses 
of intrathecal clonidine (as much as 450µg) without local anaesthetics 
provide sedation and intense and long lasting postoperative analgesia, are 
inadequate for surgical anaesthesia and for this reason, clonidine has been 
used as an adjuvant to local anaesthetics rather than used alone.9 
Dexmedetomidine also an α-2 adrenergic agonist is pharmacologically 
related to clonidine and is the most recent agent in this group approved by 
FDA in 1999 for the use in humans as short term medication (<24 hrs) for 
analgesia and sedation in intensive care unit. Its unique properties render it 
suitable for sedation and analgesia during the whole of perioperative period. 
Various studies have also found that intravenous dexmedetomidine can 
decrease the haemodynamic response to laryngoscopy and intubation.13 
Dexmedetomidine is a highly specific and selective alpha- 2 
adrenoceptor agonist with8 times more affinity for alpha- 2 adrenoceptor 
than clonidine. The ratio of alpha- 1:alpha- 2 receptor binding selectivity 
for dexmedetomidine is 1:1620 compared to 1:220 for clonidine.13While 
clonidine has been used as an adjuvant to local anaesthetic agents for 
intrathecal purposes with successful results, there are only a few studies 
available for dexmedetomidine for such studies.Hence, we have undertaken 
this study to evaluate and compare the efficacies of clonidine and 
dexmedetomidine as an adjuvant tointrathecal hyperbaric 0.5% bupivacaine 
in patients scheduled for elective lower limb surgeries. 
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AIM OF THE STUDY 
 
 
 
The present study was undertaken to evaluate and compare the efficacy 
of dexmedetomidine and clonidine added as an adjuvant to 0.5% hyperbaric 
bupivacaine intrathecallyfor elective lower limb surgeries, with respect to 
 
1. Block characteristics 
2. Haemodynamic changes  
 
3. Adverse effects  
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ANATOMY 
 
 
 
Spinal anaesthesia results in sympathetic blockade, sensory analgesia, 
anaesthesia and motor blockade. It depends on the dose, concentration, 
volume of local anaesthetic injected into the subarachnoid space. 
The vertebral canal extends from the foramen magnum to the sacral 
hiatus. There are seven cervical, twelve thoracic and five lumbar vertebrae. 
The sacrum comprises five and the coccyx four fused segments. The adult 
spine presents four curvatures: those of the cervical and lumbar zones are 
convex forwards (lordosis), whereas those of the thoracic and sacral regions 
are concave forwards (kyphosis).The former are postural, while the latter 
are produced by the actual configuration of the bones themselves. The 
vertebrae are held together by a series of overlapping ligaments14,15 namely 
 Anterior longitudinal ligament 

 Posterior longitudinal ligament 

 Ligamentumflavum

 Interspinous ligament 

 Supraspinous ligament 

 Intervertebral discs. 
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to the lower border of first lumbar vertebra in adults. The spinal cord 
extends till the upper border of second lumbar vertebra and still lower in 
infants. 
The coverings of spinal cord from outside to inside areduramater, 
arachnoidmater, piamater. The duramater is attached to the margins of 
foramen magnum above and ends below at the lower border of the second 
sacral vertebra. The anterior and posterior nerve roots from the spinal cord 
pierce the investing layer of duramater and carry the prolongation (dural 
cuff) which blends with the perineurium of the mixed spinal nerve. 
The arachnoid mater is a thin transparent sheath closely applied to 
duramater. The subdural space is a potential space which contains only 
small amount of serous fluid to allow the dura and arachnoid to move over 
each other. 
The piamater closely invests the cord and sends delicate septa into its 
substances. From each lateral surface of the piamater, a fibrous band, the 
denticulate ligament projects into the subarachnoid space. Inferiorly the 
piamater ends as a prolongation termed as filumterminale which penetrates 
the distal end of dural sac and is attached to the periostium of coccyx. 
The subarachnoid space is filled with the cerebrospinal fluid and it 
contains the spinal nerve roots and the denticulate ligament. Lumbar 
puncture is routinely done below the second lumbar vertebra to L5-S1 
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interspace to avoid damaging the spinal cord which ends at the lower border 
of first lumbar vertebra. 
Blood supply of spinal cord16 
Blood supply of spinal cord is mainly from three longitudinal arterial 
channels, one anterior spinal artery and two posterior spinal arteries. The 
main source of blood supply to the spinal arteries is from the vertebral 
arteries. However it reaches only up to the cervical segment of the cord. The 
spinal arteries also receive blood through radicular arteries that reaches the 
cord along the roots of spinal nerves. These radicular arteries are branches 
from vertebral, ascending cervical, deep cervical, intercostal, lumbar and 
sacral arteries. 
Only few of these radicular arteries are larger in size. The 
arteriaradicularis magna, or artery of Adamkiewicz, the largest of the 
radicular arteries and it may be responsible for supplying blood to as the 
lower two-thirds of the spinal cord. Its position is variable.There is no 
anastamosis between the anterior spinal artery and the posterior spinal 
artery. So the occurrence of thrombosis in any of these arteries will cause 
spinal cord infarction. 
Venous drainage of the spinal cord is mainly through six longitudinal 
venous channels. They are anteromedian and posteromedian venous 
channels which lie in the midline and two paired anterolateral and 
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posterolateral channels. These channels join together and form a venous 
plexus, from here the venous blood drains through the radicular vein into 
segmental veins; the vertebral veins in the neck, the azygos veins in the 
thorax, lumbar veins in the abdomen and lateral sacral veins in the pelvis. 
CEREBROSPINAL FLUID16 
The cerebrospinal fluid is an ultrafiltrate of plasma secreted by choroid 
plexus of third, fourth and lateral ventricles at a rate of 0.3 to 0.5ml/min. 
The average volume ranges from 120 to 150 ml, of which 25 ml is in the 
cerebral subarachnoid space, 35 ml in the ventricles and about 75 ml is in 
the spinal subarachnoid space . It is a colourless liquid with slight 
opalescence due to globulin. 
Circulation of cerebrospinal fluid 
From the lateral ventricles it enters the 3rd ventricles through the 
interventricular foramina. Then it flows through the cerebral aqueduct and it 
reaches the 4th ventricle. Through the foramen of magendie and luschka in 
the roof of the 4th ventricle it enters the subarachnoid space and circulates 
over the cerebral hemispheres and around the spinal cord. 
Absorption 
 
The main site of cerebrospinal fluid absorption is into the venous 
system through the arachnoid villi and arachnoid granulations. These are 
most numerous in superior saggital sinus and its lateral lacunae. 
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Approximately 300-380 ml of cerebrospinal fluid enters venous circulation 
each day.It  plays  an  important  role  in  spinal anaesthesia as a media  
fordispersionof  the  local  anaesthetic  drug  to the  spinal  nerve. 
Specificgravity of the injected solution is an important factor in determining 
the spread of the local anaesthetic drug in the subarachnoid space. 
SITE OF ACTION OF LOCAL ANAESTHETIC DRUGS17 
 
Local anaesthetic solution injected into the subarachnoid space mixes 
with the cerebrospinal fluid and comes into contact with the spinal cord and 
the peripheral nerve roots. The nerve roots leaving the spinal canal are 
readily exposed to the local anaesthetic solution as they are not covered 
with epithelium. 
Zone of Differential Blockade 
 
In subarachnoid block, sympathetic fibres are blocked two to six 
segments higher than the sensory fibres. Sympathetic block will be greater 
when more concentrated solutions are used or when adrenaline is added. 
Motor block will be two segments below the sensory block. 
Spread of local anaesthetics in subarachnoid space 
The local anaesthetic solution is diluted by CSF and therefore its 
original concentration is less than the actual mass of drug injected. Spread is 
also determined by the baricity of the injected solution. Baricity is a ratio 
comparing the density of a local anaesthetic solution at a specific 
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temperature to the density of CSF at the same temperature. 
A hypobaric solution has a baricity less than 1.0000 or specific gravity 
less than 1.0069 (the mean value of specific gravity). A hyperbaric solution 
has a baricity greater than 1.0000 or specific gravity more than 1.0069. 
Hypobaric and Hyperbaric solutions are prepared from isobaric solutions by 
the addition of various amounts of sterile distilled water and dextrose 
respectively. 
Isobaric solutions do not move under the influence of gravity in the 
CSF. Hyperbaric solutions, being heavier than CSF, settle to the most 
dependent aspect of the subarachnoid space, which is determined by the 
position of the patient. In supine patient, hyperbaric solutions gravitate to 
the thoracic kyphosis. Hypobaric solution floats up against the gravity to the 
nerves innervating the surgical site. 
Fate of local anaesthetics in subarachnoid space 
After injection of local anaesthetic solution into subarachnoid space, 
its concentration falls rapidly. The initial steep fall is due to mixing with 
CSF and subsequent absorption into nerve roots and spinal cord. The 
removal of local anaesthetic solution following subarachnoid injection is 
primarily by vascular absorption.Depending on the type of the drug used, it 
is metabolized in plasma by pseudo cholinesterase or in the liver. The 
addition of a vasoconstrictor to the local anaesthetic solution will decrease 
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the absorption of the drug and thus increase the duration of anaesthesia. 
 
PHYSIOLOGICAL EFFECTS OF SUBARACHNOID BLOCK 
 
Cardiovascular effects 
 
Vasomotor tone is determined by sympathetic fibers arising from T5 to 
L1 and innervating arterial and venous smooth muscle. Hence sympathetic 
block will cause a decrease in blood pressure that may be accompanied by a 
decrease in heart rate. With high sympathetic block, sympathetic cardiac 
accelerator fibers arising at T1-T4 are blocked, leading to decreased cardiac 
contractility. Bezold-Jarisch reflex has been implicated as a cause of 
bradycardia, hypotension and cardiovascular collapse after central neuraxial 
anaesthesia, in particular spinal anaesthesia. 
Respiratory effects 
 
Even with high thoracic levels, the tidal volume remains unchanged. A 
small decrease in vital capacity is due to paralysis of abdominal muscles 
necessary for forced exhalation and not due to phrenic nerve involvement or 
impaired diaphragmatic function. Effective coughing and clearing of 
secretions may get affected with higher levels of block. Respiratory arrest 
associated with spinal anaesthesia is rare and is due to hypo perfusion of 
respiratory centers in brain stem 
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Gastrointestinal function 
 
Nausea and vomiting is seen in upto 20% of patients. It is due to 
gastrointestinal hyperperistalsis caused by unopposed parasympathetic 
activity. Vagal tone dominance results in a small contracted gut with active 
peristalsis and can provide excellent operative conditions. Hepatic blood 
flow will decrease with reductions in mean arterial pressure. 
Renal function 
 
Renal function has a wide physiological reserve. Decrease in renal 
blood flow is of little physiological importance. Neuraxial blocks are a 
frequent cause of urinary retention which delays discharge of outpatients 
and necessitates bladder catheterization of inpatients. 
Complications of subarachnoid block 
 
The Immediate complications include 
 
 Hypotension 

 Bradycardia 

 Toxicity due to intravascular injection 

 Allergic reaction to local Anaesthetic 

 Hypoventilation (brain stem hypoxia) 
 
The late complications include 
 
 Postdural puncture headache 

 Retention of urine 
14 
 

 Backache 

 Meningitis 

 Transient neurological symptoms 

 Cauda equine syndrome 

 Anterior spinal artery syndrome 

 Horner’s syndrome 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sw
wa
ag
pe
CH
(2,
 
 
PHAR
 
Bupiva
eden by A
s in 1963
ents avail
ripheral n
 
EMICA
Bupiva
6-dimethy
 
 
 
 
 
 
MACO
caine, an 
.F Eken
 by L.J T
able, whi
erve block
L STRUC
caine 
lphenyl) 
LOGY 
amino am
stam and 
eluvio. I
ch is exte
s. It is a w
TURE O
has  
piperidine
1
OF BUP
ide local 
his collea
t is one o
nsively u
hite crys
F BUPI
 an   IUPA
-2-carbox
5 
IVACA
anaesthet
gues in 19
f the long
sed for in
talline po
VACAIN
C   nome
amide 
INE18,1
ic was firs
57. First 
 acting l
trathecal
wder solu
E 
nclature  
9,20
 
t synthes
report of 
ocal anae
, extradur
ble in wa
 of   1-bu
ized in 
its use 
sthetic 
al and 
ter 
tyl-n-
 
16 
 
 
Physiochemical properties21 
Molecular formula : C18 H28 N2OHCl 
Molecular weight : 288.43 g/mol 
Protein binding : 95% 
pH of saturated solution : 5.2 
pKa : 8.1 
Specific gravity : 1.021 at 37 °C 
 
Mechanism of action22,23 
 
Mechanism of action of bupivacaine is similar to that of any other 
local anaesthetic. The primary action of local anaesthetics is on the cell 
membrane axon, on which it produces electrical stabilization. Bupivacaine 
prevents transmission of nerve impulses (conduction blockade) by 
inhibiting passage of sodium ions through ion-selective sodium channels in 
nerve membranes. 
The sodium channel is a specific receptor for local anaesthetic 
molecules. Failure of sodium ion channel permeability to increase slows the 
rate of depolarization such that threshold potential is not reached and thus 
an action potential is not propagated. Local anaesthetics do not alter the 
resting transmembrane potential or threshold potential. 
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The mechanism by which local anaesthetics block sodium conductance 
is as follows 
1. Local anaesthetics in the cationic form act on the receptors 
within the sodium channels on cell membrane and block it. The local 
anaesthetics can reach the sodium channel either via the lipophilic 
pathway directly across the lipid membrane, or via the axoplasmic 
opening. This mechanism accounts for 90% of the nerve blocking 
effects of amide local anaesthetics.  
2. The second mechanism of action is by membrane expansion. This 
is a nonspecific drug receptor interaction.  
Other site of action targets 
 
 Voltage dependent potassium ion channels 

 Calcium ion currents (L-type most sensitive) 

 G protein coupled receptors 
 
 
Dosage depends on 
 
Area to be anaesthetized 
 
Number of nerve segments to be blocked 
 
Individual tolerance 
 
Technique of local anaesthesia 
 
Vascularity of area 
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Anaesthetic potency 
 
Hydrophobicity appears to be a primary determinant of intrinsic 
anaesthetic potency and Bupivacaine is highly hydrophobic, hence is very 
potent. 
Onset of action 
 
The onset of conduction blockade is dependent on the dose or 
concentration of the local anaesthetic. The onset of action of Bupivacaine is 
between 4 – 6 mins and maximum anaesthesia is obtained between 15 – 20 
minutes. 
Duration of block 
 
The duration of anaesthesia varies according to the type of block. The 
average duration of peridural block is about 3.5 – 5 hours, for nerve block 
5-6 hours and for intrathecal block, it is about 1.5 to 2 hours. 
PHARMACOKINETICS 
 
The concentration of Bupivacaine in blood is determined by the 
amount injected, the rate of absorption from the site of injection, the rate of 
tissue distribution and the rate of biotransformation and excretion of 
Bupivacaine.Bupivacaine can be detected in the blood within 5 minutes of 
infiltration or following epidural or intercostal nerve blocks. Plasma levels 
are related tothe total dose administered. Peak levels of 0.14 to 1.18 µg/ml 
were found within 5 mins to 2 hrs, and they gradually declined to 0.1 to 
0.34 µg/ml by 4 hrs. 
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Plasma binding 
 
In plasma, drug binds avidly with protein to the extent of 70 -90%. The 
rank order of protein binding for this and its homologues is bupivacaine, 
mepivacaine, lidocaine. Conversely, the unbound active fraction is one 
seventh of lidocaine and one fifth of mepivacaine 
Absorption 
 
The site of injection, dose and addition of a vasoconstrictor determine 
the systemic absorption of Bupivacaine .The maximum blood level of 
Bupivacaine is related to the total dose of drug administered from any 
particular site. Absorption is faster in areas of high Vascularity. 
Toxicity 
 
The toxic plasma concentration is set at 4 - 5 µg/ml. Maximum plasma 
concentration rarely approach toxic levels. 
 
Distribution 
 
Rapid distribution phase: (α) 
 
In this phase the drug is distributed to highly 
vascular region. Half-life of α- being 2.7 minutes. 
Slow disappearance phase: (β) 
 
In this phase the drug distributes to slowly equilibrating tissues. 
 
Half-life of (β)- being 28 minutes. 
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Biotransformation and excretion phase: (δ) 
 
Half-life of δ is 3.5 hours, clearance is 0.47litre/minute. 
 
More highly perfused organs show higher concentrations of the drug. 
Bupivacaine is rapidly excreted by lung tissue. Though skeletal muscle does 
not show any particular affinity for bupivacaine it is the largest reservoir of 
the drug. 
Biotransformation and Excretion 
 
 
Bupivacaine undergoes enzymatic degradation primarily in the liver. 
The excretion occurs primarily via the kidney. Renal perfusion and factors 
affecting urinary pH affect urinary excretion. Less than 5% of Bupivacaine 
is excreted via the kidney unchanged through urine 
The major portion of injected agent appears in urine in the form of 
2,6pipecolyoxylidine(ppx) which is a n-dealkylated metabolite of 
bupivacaine. Renal clearance of the drug is related inversely to its protein 
binding capacity and pH of urine. 
PHARMACODYNAMICS 
 
Central Nervous System 
 
Bupivacaine readily crosses the blood brain barrier causing CNS 
depression following higher doses. The initial symptoms involve feeling of 
light-headedness and dizziness followed by visual and auditory 
disturbances. Disorientation and drowsiness may occur. Objective signs are 
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usuallyexcitatory in nature, which includes shivering, muscular twitches 
and tremors, initially involving muscles of the face (perioral numbness) and 
part of extremities. 
At still higher doses cardiovascular or respiratory arrest may occur. 
Acidosis increases the risk of CNS toxicity from Bupivacaine, since an 
elevation of PaCO2 enhances cerebral blood flow, so that more anaesthetic 
is delivered rapidly to the brain 
Autonomic nervous system 
 
Bupivacaine does not inhibit the Noradrenaline uptake and hence has 
no sympathetic potentiating effect. Myelinated preganglionic B fibers have 
a faster conduction time and are more sensitive to action of Bupivacaine. 
When used for conduction blockade, all local anaesthetics, particularly 
Bupivacaine produces higher incidence of sensory than motor fibers. 
Cardiovascular System 
 
The primary cardiac electrophysiological effect of a local anaesthetic is 
a decrease in the maximum rate of depolarization in Purkinje fibers 
andventricular muscle. This action by Bupivacaine is far greater compared 
to Lignocaine. Also, the rate of recovery of block is slower with 
Bupivacaine.Therefore there is complete restoration of Vmax between 
action potential particularly at higher rates. Therefore Bupivacaine is highly 
arrythmogenic. Bupivacaine reduces the cardiac contractility by blocking 
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the calcium transport. Low concentration of Bupivacaine produces 
vasoconstriction whereas high doses cause vasodilatation. 
Respiratory System 
 
Respiratory depression may be caused if excessive plasma level is 
reached which in turn results in depression of medullary receptor center. 
Respiratory depression may be also caused by paralysis of respiratory 
muscles of diaphragm as may occur in high spinal or total spinal 
anaesthesia. 
Adverse Effects 
 
Adverse effects are encountered in clinical practice mostly due to 
overdose, inadvertent intravascular injection or slow metabolic degradation. 
Central nervous system 
 
It is characterized by excitation or depression. The first manifestation 
may be nervousness, dizziness, blurring of vision or tremors, followed by 
drowsiness, convulsions, unconsciousness and respiratory arrest. 
Cardiovascular system 
 
Myocardial depression, hypotension, arrhythmia, ventricular type 
conduction defect, SA node depression and cardiac arrest 
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PHARMACOLOGY OF DEXMEDETOMIDINE24,25 
 
 
 
 
Dexmedetomidine is the d-enantiomer of medetomidine, belongs to the 
imidazole subclass of α2 receptor agonists. It is a more selective α2 agonist 
with a 1600 greater selectivity for the α2 receptor compared with the α1 
receptor. It was introduced in clinical practice in 1999 and the only FDA 
approved use of dexmedetomidine is for sedation in mechanically ventilated 
patients in intensive care unit. It is now being used off-label outside of the 
ICU in various settings, including sedation and adjunct analgesia in the 
operating room, sedation in diagnostic and procedure units, and for other 
applications. 
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MECHANISM OF ACTION 
 
Alpha2adrenoreceptors are membrane-spanning G proteins. There are 
three subtypes of α2 adrenergic receptors in humans: α2A, α2B, and α2C. The 
α2A receptors are distributed mainly in the periphery, likewise α2B and α2C 
receptors are primarily distributed in spinal cord and brain. 
Postsynaptic α2 receptors in the peripheral blood vessels produce 
vasoconstriction, whereas α2 receptors located in the presynaptic region 
inhibit the release of norepinephrine, potentially attenuating the 
vasoconstriction. These receptors are involved in the sympatholysis, 
sedation, and antinociceptive effects of α2 receptors. 
PHARMACOKINETICS 
 
Dexmedetomidine when injected intravenously, it is rapidly distributed 
in the body and it is metabolized mainly in the liver and excreted in urine 
and faeces. Dexmedetomidine is 94% protein bound. The elimination half-
life of dexmedetomidine is around 2 hours and with a context-sensitive half-
time of 4 minutes to 250 minutes after an 8-hour infusion. Volume of 
distribution is 118 litres. Clearance is estimated to be approximately 
39litres/ hour. 
Central nervous system 
 
Sedation 
 
Dexmedetomidine acts on the alpha 2 receptors in locus ceruleus and 
causes sedation as well as hypnosis. It exerts sedative effect by acting 
through the endogenous sleep-promoting pathways. 
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Analgesia 
 
Analgesia produced by dexmedetomidine is complex and not clearly 
known. The spinal cord is thought to be the primary site of action. It causes 
analgesia when injected either in intrathecal or epidural space. 
Respiratory System 
 
When dexmedetomidine is given at doses required to produce 
significant sedation it reduces minute ventilation, but the response to 
increase in carbon dioxide concentration is preserved. Ventilatory changes 
caused by dexmedetomidine is identical to the changes that appear during 
normal sleep. 
Cardiovascular System 
 
Dexmedetomidine causes a decrease in heart rate, myocardial 
contractility, cardiac output, systemic vascular resistance and blood 
pressure myocardial contractility and cardiac output. Dexmedetomidine 
when given in bolus dose has shown a biphasic response. Rapid injection of 
dexmedetomidine in a dose of 2 µg/kg causes a brief rise in the blood 
pressure (22%) and a decrease in the heart rate (27%) from the base line 
valve.This brief rise in blood pressure is due to the stimulation of peripheral 
alpha 2 receptors which causes vasoconstriction. After 15 minutes the heart 
rate came back to the baseline level, and blood pressure gradually declined 
to approximately 15% below baseline by 1 hour. 
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USES 
 
Dexmedetomidine is used for sedation in mechanically ventilated 
patients and for procedural sedation prior to or during surgery.In 
operating room, it is used for premedication and a sole anaesthetic in 
monitored anaesthesia care. It is also used as an adjunct with 
localanaesthetic drugs in peripheral nerve block, intravenous regional 
anaesthesia, epidural and spinal anaesthesia. 
Intensive care unit 
 
Dexmedetomidine has several advantages over propofol while sedating 
postoperative patients in intensive care units. It reduces opioids 
consumption, PaO2/FIO2 ratio was significantly higher and heart rate was 
slower in dexmedetomidine group. Due to its unique character of providing 
good sedation with less respiratory depression it can be used while weaning 
patients from the ventilator. 
Anaesthesia 
 
Dexmedetomidine when used as a premedicant it reduces the 
requirements of induction agents, volatile anaesthetics and opioids. It 
suppresses the hemodynamic response to intubation. When used in 
ophthalmic cases it reduces the intraocular pressure and catecholamine 
secretion is reduced. Perioperative analgesic requirements are less, and 
recovery is more rapid. In a morbidly obese patient, the narcotic-
sparingeffect of dexmedetomidine was evident in the intraoperative and 
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postoperative period after bariatric surgery.Dexmedetomidine has been 
successfully used in the treatment of withdrawal of narcotics, 
benzodiazepines, alcohol, and recreational drugs. It is also used for 
procedural sedation in paediatric patients. 
Dosage and administration: 
 
For adults, dexmedetomidine is administered intravenously at a 
loading dose of 0.5 to 1 µg/kg as a slow infusion over a period of ten 
minutes, followed by a maintenance infusion of 0.2 to 0.7 
µg/kg/hr.Dexmedetomidine should be diluted in 0.9 % normal saline for 
infusion. Dexmedetomidine is recommended for infusion lasting up to 24 
hrs. It is freely soluble in water. 
Adverse effects: 
 
Major adverse effects include transient hypertension, hypotension 
haemorrhage, bradycardia, atrial fibrillation, sinus tachycardia, sinus arrest, 
ventricular tachycardia, myocardial infarction, agitation, confusion, 
delirium, hallucination, illusion and dry mouth 
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PHARMACOLOGY OF CLONIDINE 
  
Clonidine is a centrally acting selective partial alpha2 -adrenergic 
agonist (220:1 alpha2 to alpha1) that acts as an antihypertensive drug by 
virtue of its ability to decrease sympathetic nervous system output from 
central nervous system.26 
 
 
Structural Formula 
 
 
 
 
 
 
 
 
 
 
 
 
Pharmacokinetics26 
 
Clonidine is rapidly and almost completely absorbed from 
gastrointestinal tract. The bioavailability is nearly hundred percent. After 
oral intake, peak plasma concentration reaches within 60 to 90 minutes. The 
elimination half life of clonidine is between 9 and 12 hours, with 
approximately 50% metabolized in the liver whereas the rest is excreted 
unchanged in urine. The transdermal route requires about 48 hours to 
produce therapeutic plasma concentrations. Clonidine can be administered 
via nasal, oral, intravenous, intramuscular, transdermal, epidural and 
intrathecal route. Clonidine is metabolized mainly by the liver to produce P-
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hydroxy clonidine which subsequently undergoes glucuronidation and is 
excreted in urine. 
Pharmacodynamics 
 
Analgesic effects 
 
Activation of post synaptic alpha2 receptors in the substantiagelatinosa 
of the spinal cord is the presumed mechanism by which clonidine produces 
analgesia. 
Alpha2-Adrenoceptors are located on primary afferent terminals (both 
at peripheral and spinal endings), on neurons in the superficial laminae of 
the spinal cord, and within several brainstem nuclei implicated in analgesia, 
supporting the possibility of analgesic action at peripheral, spinal, and 
brainstem sites.9 
The cardiovascular effects 
  
Action of clonidine on cardiovascular system classified as peripheral 
and central. Clonidine affects blood pressure in a complex fashion after 
neuraxial or systemic administration because of opposing actions at 
multiple sites. In the nucleus tractussolitarius and locus ceruleus of the 
brainstem, activation of postsynaptic alpha2-adrenoceptors reduces 
sympathetic drive. In addition, clonidine is not a pure alpha2/alpha1 
adrenergic agonist; it also activates nonadrenergicimidazoline-preferring 
binding sites in the lateral reticular nucleus, thereby producing hypotension 
and an antiarrythmogenic action. In the periphery, activation of presynaptic 
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alpha sub2-adrenoceptors at sympathetic terminals reduces their release of 
norepinephrine by the sympathetic nerve terminals, which could cause 
vasorelaxation and reduced chronotropic drive. These brainstem and 
peripheral effects of alpha2 -adrenoceptor stimulation are counter-balanced 
by direct peripheral vasoconstriction from circulating concentrations of the 
alpha2/alpha1 adrenergic agonist, clonidine. As a result, the dose response 
for clonidine by neuraxial or systemic administration is U-shaped, with 
peripheral vasoconstriction from circulating drug concentrations at high 
doses opposing central sympatholysis.9 
Clonidine reduces heart rate partly by a presynaptically mediated 
inhibition of norepinephrine release at the neuroreceptor junction and partly 
by a vagomimetic effect. Clonidine depresses atrioventricular nodal 
conduction.9 
Clonidine and haemodynamic response to intubation 
 
Various studies have shown that, IV clonidine administration before 
laryngoscopy and intubation, in the dose of 3µg kg-1 to 6 µg kg-1 effectively 
attenuated the haemodynamic response to intubation. 
 
Respiratory effects 
 
Clonidine has minimal respiratory depressant effect on ventilation and 
do not potentiate ventilatory depressant effect of opioid26. It must be 
considered that drugs acting on the central nervous system to alleviate pain, 
relieve anxiety, and produce sedation are almost always accompanied by 
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some reduction in alveolar ventilation. 
Central nervous system 
 
Sedation commonly accompanies the use of clonidine. Clonidine 
increases stage I and stage II sleep with decrease in rapid eye movement. It 
causes anxiolysis. Anaesthetic-sparing properties of alpha2-adrenergic 
agonists by inhibitory actions in the locus ceruleus via a G-protein mediated 
mechanism that involves inhibition of adenylatecyclase and decreases 
requirement for inhaled anaesthetic (MAC) and injected drugs. Clonidine 
produces dose-dependent sedation over the dose range 50-900 micro gram 
of rapid onset (< 20 min) regardless of route of administration. 
Renal system 
 
Clonidine hastens time to first micturition after spinal 
anaesthesia.Clonidine induces diuresis. Mechanism for diuresis is inhibition 
of release of antidiuretic hormone (ADH), antagonism of renal tubular 
action of ADH and increase in glomerular filtration. 
 
Hormonal effects 
 
Clonidine decreases plasma catecholamine levels. In stress situations, 
it reduces, but does not suppress, the neurohormonal secretion 
(norepinephrine, epinephrine, adrenocorticotrophic hormone, cortisol) 
secondary to sympathoadrenalhyperactivation. 
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Uses of Clonidine 
  
1. Clonidine is very effective in the treatment of patient with severe 
hypertension or renin dependant disease.  
2. Clonidine is used aspreanesthetic medication, 
 
3. Preservative free clonidine administered into the epidural or 
subarachnoid space (150 to 450 µg) produces dose dependent 
analgesia.9 
4. Addition of clonidine 1 µg/kg, to lidocaine for Bier’s block 
enhances postoperative analgesia.  
 
5. Clonidine protects against perioperative myocardial ischemia.  
 
6. Clonidine used for the diagnosis of pheochromocytoma.  
 
7. Used for the treatment of opioid and alcohol withdrawal syndrome.  
8. Used in the treatment of shivering. 
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REVIEW OF LITERATURE 
 
 
1. Benhamou D et al 27in 1998 compared analgesic efficacy and side 
effectprofile of intrathecal clonidine and fentanyl with hyperbaric bupivacaine 
during elective cesarean section. Study group consisted of 78 ASA I and II 
pregnant women who were scheduled for elective cesarean section. Group B 
received hyperbaric bupivacaine 0.06 mg/cm of body height and 1 ml saline. 
Group BC received hyperbaric bupivacaine 0.06 mg/cm of body height with 
clonidine 75µg (0.5 ml) and saline (0.5 ml). Group BCF received fentanyl 
12.5 µg (0.5 ml) and clonidine 75 µg with hyperbaric bupivacaine. Combined 
spinal epidural anaesthesia performed in 34 patients out of 78. When data 
were compared for patients who received only the initial spinal injection, time 
of regression to two segments and time to request of first analgesic were 
significantly longer only in group BCF. They concluded that by using small 
dose of intrathecal clonidine to bupivacaine improves intraoperative analgesia 
with no side effects. Combination of clonidine and fentanyl further improved 
analgesia but with moderately increased sedation and pruritis. 
 
2. De KockM et al28in 2001studied the effect of 
intrathecalropivacaineand clonidine for ambulatory knee arthroscopy.In this 
study 120 ASA grade I patients scheduled for elective knee arthroscopy was 
divided into four groups. Group 1 patients received 8 mg of ropivacaine, group 
2 patients received 8 mg of ropivacaine plus 15 µg clonidine,group 3 patients 
received 8 mg ropivacaine plus 45 µg clonidine and group 4 patients received 
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ropivacaine 8 mg plus 75µg clonidine.A combined spinal epidural technique 
was performed in the lateral position at L3-L4 interspace using a midline 
approach. 
Intrathecalropivacaine (8 mg alone) produced short sensory anaesthesia 
and motor blockade (132 ± 38 min and 110 ± 35 min) and the quality of 
anesthesia was significantly lower than in any other group. Ropivacaine (8 
mg) with 75 µg clonidine produced significantly longer sensory and motor 
anesthesia(195 ± 40 min and 164 ± 38 min) and was associated with systemic 
effects, such as sedation and reduction of arterial blood pressure, but without 
bradycardia. Ropivacaine (8 mg) with 45 µg clonidine increased the duration 
of sensoryblockade (183 ± 52 min) and had no influence on motor blockade or 
time to walk but was associated with delayed micturition and relative 
hypotension. Ropivacaine (8 mg) with 15µg clonidine did not prolong sensory 
or motor blockade, but produced high quality anaesthesia. 
Authors concluded that the association of low dose clonidine (15 µg) 
with 8 mg ropivacaine for ambulatory arthroscopy significantly improves the 
subjective parameters that reflect the quality of intraoperative analgesia, and 
without compromising earlymobilization or interferring systemic side effects. 
3. Dobrydnjov I et al 29in 2003 studied clonidine combined with small 
dosebupivacaine during spinal anesthesia for inguinal herniorrhaphy.    45 
ASA I and II patients were randomly allocated to one of the three groups, each 
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comprising 15 patients. Group B received 0.5% hyperbaric bupivacaine 6 mg. 
Patients in group BC15 received clonidine 15 µg along with 6 mg of 0.5% 
hyperbaric bupivacaine. Patients in group BC30 received clonidine 30 µg 
along with 6 mg of 0.5% hyperbaric bupivacaine. All test solutions were 
diluted with saline to a total volume of 3 ml. Intensity and duration of motor 
and sensory block, duration of analgesia, hemodynamic stability, sedation and 
adverse effects such as pruritis, postoperative nausea and vomiting, headache 
and low back pain was assessed.The authors concluded that addition of 
intrathecal clonidine to small dose of bupivacaine increased the spread and 
duration of analgesia and produced an effective spinal anesthesia. Clonidine 
15 µg combined with bupivacaine 6 mg did not produce prolonged 
postoperative motor block and is therefore to be preferred for ambulatory 
inguinal herniorrhaphy. 
 
4. Strebel S et al 30in 2004 studied the effect of small dose 
intrathecalclonidine and isobaric bupivacaine for orthopedic surgery. Eighty 
ASA I-III patients scheduled for elective hip or knee arthroplasties were 
randomly assigned to receive intrathecal isobaric 0.5% bupivacaine 18 mg, 
plus saline (Group 1) or clonidine 37.5 µg (Group 2) or clonidine 75 µg 
(Group 3) or clonidine 150 µg (Group 4). All patients received a coded 
intrathecal drug volume of 4.6 ml.Time to regression of spinal anaesthesia 
below level L1 was 288±62 mins in control group, 311±101 mins in group 2, 
325±69 min in group 3 and 337±78 mins in group 4.The time interval between 
spinal anesthesia and the first request for supplemental PCA morphine was 
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295±80 min in control group, 343±75 min (group 2), 381±117 min (group 3) 
and 445±136 min (group 4). The range of the upper level of sensory blockade 
was similar in all groups. A complete motor blockade of the lower extremities 
was observed in all patients. After 4, 5, 6 and 7 hours, the Bromage grade was 
significantly higher in group 4 compared in the group 1.There were no inter 
group differences in the number of patients with a MAP decrease ≥ 30% or in 
the maximal decrease of MAP. There was no significant difference in sedation 
scores or in the intraoperative use of midazolam among the groups. 
 
Authors concluded that the addition of intrathecal clonidine at doses≤150 
µg to isobaric bupivacaine dose dependently prolongs both sensory blockade 
of spinal anesthesia and time interval to first request for supplemental 
analgesia.  
5. KanaziG E et al 31in 2005conducted a prospective, double blindstudy 
in 60 patients undergoing transurethral resection of prostate or bladder tumour 
under spinal anaesthesia. The aim was to compare the onset and duration of 
sensory and motor block, hemodynamic changes and level of sedation 
following intrathecal administration of bupivacaine with either 
dexmedetomidine or clonidine. 
60 patients were randomly allocated into 3 Groups. Group B received 12 
mg of hyperbaric bupivacaine, Group D received 12 mg of bupivacaine 
supplemented with 3µg of dexmedetomidine; Group C received 12 mg of 
bupivacaine supplemented with 30µg of clonidine. 
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The mean time to reach T10 sensory block was 9.7 ± 4.2 minutes in 
Group B, 7.6 ± 4.4 minutes in Group C, 8.6 ± 3.7 in Group D. The mean time 
to reach peak sensory level was 20.2 ± 8.4 minutes in Group B, 18.7 ± 9.2 
minutes in Group C, 24.5 ± 14.8 minutes in Group D. The mean time to reach 
Bromage 3 was 13.2 ± 5.6 in Group D, 11.7± 5.9 minutes in Group C, 20.7 ± 
10.3 minutes in Group B.The time taken for regression of sensory block by 
two segments was 80±28 mins in Group B, 101±37 mins in Group C and 
122±37 mins in Group DThe mean values of MAP and heart rate were 
comparable between 3 Groups throughout the intra op and post-operative 
period. All patients had oxygen saturation > 96% at all times and did not 
require additional oxygen in PACU. 
 
They concluded that supplementation of spinal bupivacaine with low 
dose of intrathecal dexmedetomidine or clonidine produces significantly 
shorter onset of motor block and significantly longer sensory and motor block 
than bupivacaine alone. Dexmedetomidine 3µg and Clonidine 30µg have a 
equipotent effect on the characteristics of the block without any significant 
hemodynamic instability or sedation. 
6. Kaabachi O et al32in 2007 studied spinal anesthesia in adolescents 
withplain bupivacaine and clonidine 1µg/kg with regards to safe and effective 
adjuvant for spinal anesthesia.The study group consisted of 83 adolescents 
38 
 
aged between 10 to 16 years, scheduled for orthopaedic surgeries of lower 
extremities. Control group received plain 0.5% bupivacaine alone and 
clonidine group received clonidine 1 µg /kg along with bupivacaine. Isobaric 
bupivacaine 0.5%, at a dose of 0.2 to 0.4 mg/kg of body weight up to 15 mg 
was given. Volume of injection was 0.1 to 0.5 ml larger in clonidine group due 
to the addition of clonidine. Non-invasive blood pressure, heart rate and 
arterial oxygen saturation were assessed at baseline and every 2 min for the 
first 10 min after spinal injection, and thereafter, every 5 minute during the 
surgery.Sensory and motor blocks were assessed at 15 and 30 min after 
intrathecal injection and every 5 min in the post anaesthesia care unit. 
Postoperative pain was assessed using an 100 mm visual analog scale every 
hour during first 6 hours and at every 3-4 hours thereafter and rescue analgesia 
given with tramadol 1-2 mg/kg iv if the pain score was 30 mm or higher. 
 
They observed similar cephalic spread of the sensory block in the two 
groups, but the time to regression of the sensory block by two segments was 
significantly longer in the clonidine group. Duration of analgesia was 
prolonged in clonidine group (461±147 min) when compared to control group 
(330±138 min). Motor blockade was similar in two groups, but the time to 
recovery of motor block was significantly longer in clonidine group (252±79 
min) when compared to placebo group (181±59 min).Authors also noted that 
the first dose of rescue analgesic was longer in the clonidine group than the 
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control group.Number of patients who developed hypotension was 29% in 
clonidine group and 17% in placebo group. Number of patients who developed 
bradycardia was 21% in clonidine group and 12% in placebo group.Authors 
concluded that adding clonidine 1 µ/kg to bupivacaine prolongs spinal 
anesthesia in adolescents without causing severe adverse effects. 
7. Sethi BS et al33in 2007 studied the efficacy of analgesic effects of 
lowdose intrathecal clonidine as adjuvant to bupivacaine. 60 ASA I and II 
patients in the age group of 20-50 years scheduled to undergo lower 
abdominal surgeries were randomly divided into two groups of 30 each. 
Clonidine group patients received 0.5% hyperbaric bupivacaine 12.5 mg with 
preservative free clonidine 1µg/kg. Control group patients received 0.5% 
hyperbaric bupivacaine 12.5 mg with identical volume of saline. The degree of 
sensory block, motor block, parameters like HR,NIBP, ECG and SpO2 were 
recorded at 5 min interval. They showed that decrease in mean heart rate and 
MAP from 45 minutes until the end of 6 hours was greater in clonidine group 
than in control group and was statistically significant though, no patient had a 
fall of MAP to <70 mmHg in both the group and hence did not require 
additional vasopressor and fluid therapy and no patient in both the groups had 
a decrease in heart rate less than 60/minute and hence did not require injection 
atropine sulphate. The level of sensory regression by two segments was 218 
minutes in the clonidine group and 136 min in the control group. The duration 
of motor blockade was 205 minutes in clonidine group and 161 minutes in 
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control group.Duration of analgesia was 614 minutes in clonidine group and 
223 minutes in control group. The number of diclofenac sodium injection 
required in 24 hours was higher in control group than clonidine group.The 
sedation score were higher in clonidine group than control group. They 
concluded that addition of clonidine to bupivacaine in the dose of 1 µg/kg 
significantly increases the duration of analgesia compared to bupivacaine 
alone without significant fall in MAP and heart rate requiring therapeutic 
intervention. 
 
8. Grandhe RP et al34in2008 studied the effect of bupivacaine-
clonidinecombination for unilateral spinal anaesthesia in lower limb 
orthopedic surgery. 45 ASA I and II patients aged 20-50 years, undergoing 
unilateral lower limb surgery were allocated to receive 1.5 ml of 0.5% heavy 
bupivacaine combined with either 1 ml of normal saline (group B) or clonidine 
1 µg/kg (group BC1) or 1.5 µg/kg (group BC2). The total volume injected was 
2.5 ml in all patients.The authors observed time to achieve sensory block upto 
T11 was 7.6±2.2 mins in control group and it was 7.1±4.2 mins and 8.2±3.4 
mins in clonidine groups (BC1 and BC2 respectively). The time to achieve 
maximum sensory block was 19±2.1 mins in the control group and 18±4.6 
mins and 21±3.9 mins in clonidine groups (BC1 and BC2 respectively). The 
mean duration of analgesia was 3.8±0.7 hours in control group, 6.3±0.8 hours 
when using clonidine of 1 µg/kg with a mean weight of 60.6±19.4 kg and 
7.3±0.9 hours when using clonidine of 1.5 µg/kg with a mean weight of 
62.7±18 kg. The authors observed the mean heart rate was significantly lower 
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in group BC2 compared to group B between 105 min to 8 hours following 
intrathecal drug administration. No bradycardia occurred in any of the 
patients. The incidence of hypotension was 4patients in control group, 10 
patients in group BC1and 8 patients in group BC2. Authors concluded that the 
combination of 1-1.5 µg/kg body weight of clonidine with 1.5 ml of 0.5% 
hyperbaric bupivacaine for producing unilateral spinal anaesthesia effectively 
prolonged the sensory and motor block and postoperative analgesia while 
causing minimal adverse effects. 
 
9. Al Ghanem SM et al35in 2009 conducted a double blind controlled 
studyon the effect of adding dexmedetomidine versus fentanyl to intrathecal 
bupivacaine on spinal block characteristics in gynaecological 
procedures.Seventy-six patients of ASA Grade I-III were randomly allocated 
to one of two groups.Group D received 10 mg of isobaric bupivacaine with 
5µg dexmedetomidine and Group F received 10 mg of isobaric bupivacaine 
with 25 µg of fentanyl.The authors observed the time to reach T10 sensory 
block to be 7.5±7.4 min in Group D and 7.4±3.3 min in Group F. The time to 
reach the maximum sensory block was 19.34±2.87 min in Group D and 
18.39±2.46 min in Group F. The time to reach S1 segment was significantly 
longer in group D (274.8±73.4 min) than in Group F (179.5±47.4 min).The 
onset time motor block was not different between group D (14.4±6.7 min) and 
group F (14.3±5.7 min). The regression of motor block to Bromage 0 was 
240±64 mins in group D was significantly longer than that for Group F 
42 
 
(155±46 min).The mean values of MAP and HR were similar in both the 
groups. The sedation score was between 0 and 1 in both groups. Hypotension 
was mild to moderate in both groups except one in group F who had blood 
pressure less than 90 mmHg and required 36 mg ephedrine. The authors 
concluded that 5µg of Dexmedetomidine seems to be an attractive alternative 
as an adjuvant to spinal bupivacaine in surgical procedures especially in those 
that need quite long time with minimal side effects and excellent quality of 
spinal analgesia.  
10. Al-Mustafa et al 36in 2008conducted a study todetermine the effect 
of adding different doses of dexmedetomidine to isobaric bupivacaine for 
patients undergoing urological procedures under spinal anaesthesia.Sixty six 
patients were randomly assigned into 3 groups. Group N received Bupivacaine 
12.5mg with saline. Group D5 received 12.5mg Bupivacaine with 5µg 
Dexmedetomidine. Group D10 received 12.5mg Bupivacaine with 10µg 
Dexmedetomidine. The mean time of sensory block to reach T10 dermatome 
was 4.7 ±2 minutes in D10 group, 6.3 ±2.7 minutes in D5 group and 9.5 ± 3 
minutes in Group N .The mean time to reach Bromage 3 scale was 10.4 ± 3.4 
minutes in group D10, 13.0 ± 3.4 minutes in Group D5 and 18.0 ± 3.3 minutes 
in GroupN. The regression time to reach S1 dermatome was 338.9 ± 44.8 
minutes in Group D10, 277.1±23.2 minutes in D5 and 165.5 ± 32.9 minutes in 
Group N . The regression to Bromage 0 was 302.9± 36.7 minutes in D10 , 
246.4± 25.7 minutes in D5 and 140.1 ± 32.3 minutes in Group N. Onset and 
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regression of sensory and motor block were highly significant (N verses D5,N 
verses D10 and D5 verses D10).They concluded that dexmedetomidine has a 
dose dependent effect on the onset and regression of sensory and motor block 
when used as an adjuvant to bupivacaine in spinal anaesthesia. 
 
11. Saxena H et al 37in 2010 studied the effect of low dose 
intrathecalclonidine with bupivacaine with regards to onset and duration of 
block.80 patients of ASA grade I and II, scheduled for elective surgery below 
umbilicus were grouped into 4 groups. Group1 received hyperbaric 
bupivacaine 13.5 mg and 0.3 ml saline. Group 2 received 15 µg, group 3 
received 30 µg and group 4 received 37.5 µg clonidine added to bupivacaine. 
The total volume of drug was 3 ml in all groups.The mean time for onset of 
sensory block was significantly lower in all clonidine groups in a dose 
dependant manner compared to control group and lowest in group 4. The 
mean time to achieve sensory block up to T10 was 6.57±0.49 mins in control 
group and 2.58±0.33 mins, 2.54±0.34 mins and 2.09±0.89 mins in clonidine 
group (15 µg, 30 µg and 37.5 µg respectively). The mean time to achieve 
maximum sensory level was 7.3±1.25 mins in control group and 6.8±1.20 
mins, 7.4±1.31 mins and 6.7±1.12 mins in clonidine group (15µg, 30µg and 
37.5µg respectively). There was no statistical difference in the extent of block 
achieved in any group.The onset of motor block was 7.41±0.55 mins in 
control group and 2.67±0.50 mins, 2.30±0.45 mins, 2.20±0.50 mins in 
clonidine group (15µg, 30µg, 37.5µg respectively).The duration of analgesia 
was 99.75±21.91 mins in control group, 164.5±23.9 mins, 264.75±44.3 mins 
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and 285.60±36.59 mins in clonidine group (15µg, 30µg and 37.5µg 
respectively). The duration of motor blockade was 153±19.5 mins in control 
group, 206.75±20.16 mins, 220±47.43 mins and 235±31.9 mins in clonidine 
groups (15µg, 30µg and 37.5µg respectively).The haemodynamic parameters 
were similar in all the 4 groups at any point of time with no statistical 
variation. There was a 20% fall in the mean pressure from the baseline in 
group 4 as compared to 8% in group 1, 30 min after the injection. Authors 
concluded that addition of intrathecal clonidine to bupivacaine, even in very 
small doses, significantly improves the onset and duration of sensory and 
motor block with relative haemodynamic stability. 
 
12. Gupta R et al38in 2011 Studied dexmedetomidine as an 
intrathecaladjuvant for post-operative analgesia with isobaric 
ropivacaine.Sixty patients were randomized into 2 groups. Group R received 3 
ml of 0.75% isobaric ropivacaine with 0.5 ml normal saline, Group D received 
3 ml of 0.75% isobaric ropivacaine with 0.5 ml dexmedetomidine (5µg). They 
showed that the duration of onset of sensory blockade in Group D was 4.8±1.2 
mins and in Group R was 4.7±1.1 mins and duration to achieve maximum 
sensory blockade in Group D was 11.7±1.7 mins, in Group R was 12.1±1.6 
mins and time to 2 segment regression of sensory blockade in Group D was 
125.6±16.5 mins, in Group R was 62.7±8.3 mins and regression of sensory 
blockade to S2 in Group D was 468.3±36.8 mins, in Group R was 239.3±16.8 
mins and time for rescue analgesia in Group D was 478.4±20.9 mins, in Group 
R was 241.7±21.7 mins. Time to two segment regression of sensory blockade 
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and regression of sensory blockade to S2 were significantly slower with 
intrathecal dexmedetomidine. The duration of analgesia was significantly 
prolonged with addition of dexmedetomidine as compared to ropivacaine 
alone.Intraoperative ephedrine requirement was more in group D and two 
patients had bradycardia was treated with 0.6 mg of IV atropine. Authors 
concluded that 5µg dexmedetomidine seems to be an alternative as an 
adjuvant to spinal ropivacaine in the surgical procedures, especially those 
requiring long time. 
13. Eid HEA et al39in 2011 studied dose related effect of 
intrathecaldexmedetomidine with hyperbaric bupivacaine, a prospective 
randomized double blind study.Forty eight patients scheduled for anterior 
cruciate ligament reconstruction were randomized to one of the 3 groups 
receiving 10 µg Dexmedetomidine (Group D1), 15 µg Dexmedetomidine 
(Group D2) and normal saline with 3 ml of 0.5% hyperbaric bupivacaine 
(Group B). In all the group’s total volume of drug was 3.5 ml. The onset of 
sensory block was 8.7±3.3 mins in Group B, 7.7±3.6 mins in Group D1 and 
8±2.5 mins in Group D2. Time  to two segment regression in Group B was 
76.9±26.8 mins, Group D1 was 103±28.7 mins and Group D2 was 200.6±30.9 
mins and regression of sensory blockade to S1 in Group B was 238±57 mins, 
Group D1 was 320±65.8 mins and Group D2 was 408.7±68 mins and 
regression to Bromage 0 in Group B was 202±41.8 mins, in Group D1 was 
280±46 mins and in Group D2 was 336±58 mins.There was a dose dependent 
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prolongation of the duration of sensory block and motor block by the addition 
of intrathecal dexmedetomidine. The mean values of MAP and HR were 
comparable between the three groups throughout the study. They concluded 
that intrathecal dexmedetomidine in significantly prolonges the anaesthetic 
and analgesic effects of spinal hyperbaric bupivacaine in a dose dependent 
manner. 
14. Gupta R et al40in 2011 conducted a comparative study of 
intrathecaldexmedetomidine and fentanyl as adjuvants to bupivacaine.Sixty 
patients scheduled for lower abdominal surgeries were randomly allocated to 
receive either 12.5 mg hyperbaric bupivacaine with 5µg dexmedetomidine 
(group D) or 25µg fentanyl (group F). They showed that there was no 
difference between groups D and F in the highest level of block achieved in 
the two groups (T5 andT6 respectively) or in the time to reach peak level. 
Block regression (476±23 min in group D and 187±12 min in group F) was 
significantly slower with the addition of intrathecal dexmedetomidine as 
compared with fentanyl. There was no difference in the onset time of motor 
block (11.6±1.8 min in group D and 11.2±1.3 min in group F) but the duration 
of motor block (421±21 min in group D and 149±18 min in group F) was 
significantly slower with the addition of dexmedetomidine. The time to rescue 
analgesic was significantly longer in group D as compared to group F.The 
patients in both groups remained hemodynamicallystable, the sedation score 
was more in group D patients. Intraoperative ephedrine requirement was more 
in group D (10±4 mg) as compared to group F (6±3 mg). One patient in group 
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D had bradycardia (HR<50/min) but it was successfully managed with 
atropine 0.4 mg. Authors concluded that 5µg dexmedetomidine seems to be an 
attractive alternative to 25µg fentanyl as an adjuvant to spinal bupivacaine in 
providing good quality of analgesia, hemodynamic stability and  minimal side 
effects. 
15. Shukla D et al41in2011  compared  the  effects  of 
Intrathecaldexmedetomidine and magnesium sulfate used asadjuvants to 
bupivacaine.Ninety patients scheduled for lower abdominal and lower limb 
surgeries were randomly allocated to receive either 15 mg hyperbaric 
bupivacaine with 10µg (0.1 ml) dexmedetomidine (group D) or 50 mg (0.1 
ml) magnesium sulfate (group M) or 0.1 ml saline (group C). The onset of 
sensory blockade in Group D was 2.27±1.09 mins, in Group M was 6.46±1.33 
mins and in Group C was 4.14±1.06 min. The onset of motor blockade in 
Group D was 3.96±0.92 mins, in Group M was 7.18±1.38 mins and in Group 
C was 4.81±1.03 min, the mean time for regression of sensory blockade to S1 
in Group D was 352±45 mins, in Group M was 265±65 mins and in Group C 
was 194±55 min, mean time for regression to Bromage 1 in Group D was 
331±35 mins, in Group M was 251±51 mins and in Group C was 140±34 
mins.The onset time of both sensory and motor block was rapid in Group D 
and delayed in Group M in comparison with the control Group C and was 
statistically significant. The regression time of both sensory and motor block 
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was prolonged in Group D and in Group M in comparison with the control 
Group C and was statistically significant. There was no significant difference 
in the mean values ofmean arterial pressure and heart rate intraoperatively and 
postoperatively.Authors concluded that intrathecal dexmedetomidine 
supplementation of spinal block seems to be a good alternative to intrathecal 
magnesium sulfate as it produces earlier onset and prolonged duration of 
sensory and motor block without associated significant hemodynamic 
alterations. 
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MATERIALS AND METHODS 
 
 
Study design  : Double blinded randomised case control study. 
Sample size  : 90 patients 
Sampling method : Randomised sampling 
Statistical analysis : Chi square test 
Method of collection: All patients undergoing elective lower limb surgery 
 
After obtaining approval from the institutional ethical 
committee, Thanjavur medical college, Thanjavur, the study was 
conducted in 90 ASA grade I or II patients undergoing elective lower 
limb surgeries under spinal anaesthesia. All patients were explained 
about the procedures and an informed written consent was obtained. 
INCLUSION CRITERIA 
1. Patients aged between 18 and 60 years 
2. ASA I?II 
3. Scheduled for elective lower limb surgeries. 
EXCLUSION CRITERIA 
1. Any contraindication of regional anaesthesia, or patient  refusal. 
2. Body weight more than 120 kg 
3. Height <140 cm 
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4. Post spinal surgeries, spinal deformity 
5. History of allergy to study drugs 
6. Pregnancy 
7. Coagulopathy 
8. Cardiac, liver, or kidney diseases. 
9. Neurological disorder. 
METHODOLOGY 
Ninety patients in the age group between 20 years and 60 years of 
either sex belonging to ASA physical status I and II posted for elective 
lower limb surgerieswere grouped randomly into three groups (n=30). 
Randomization was done using sealed envelope technique. 
Group B (control group): received 15mg of 0.5% hyperbaric 
bupivacaine with 0.5ml normal saline. 
Group C (clonidine group): received 15mg of 0.5% hyperbaric 
bupivacaine with 50µg clonidine. 
Group D (dexmedetomidine group): received 15mg of 0.5% 
hyperbaricbupivacaine with 5µg dexmedetomidine. 
Total volume of the injected solution was 3.5ml in all three groups. 
 
Preoperative preparation  
 
Preoperative assessment was done for each patient and informed 
written consent was taken. Patients were kept NPO for solids 6 
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hoursand clear fluids 2 hours before surgery. All patients were 
premedicated on the night before surgery with Tablet Ranitidine 
150mg and Tablet Alprazolam 0.5mg.Intravenous line was secured 
with 18 gauge cannula and preloaded with     500 ml of Ringer 
lactatesolution half an hour before anaesthesia. 
In the operating room, appropriate equipment for airway 
management and emergency drugs were kept ready. The horizontal 
position of the operating table was checked. Patients were shifted to 
the operating room and positioned. Non-invasive blood pressure 
monitor, pulseoximeter and ECG leads were connected to the patient. 
Preoperative baseline systolic and diastolic blood pressure, mean 
arterial pressure, pulse rate, respiratory rate and oxygen saturation 
were recorded.  
Intraoperative monitoring 
On sitting position, the skin over the back was prepared with 
antiseptic solution and draped with sterile towel.Under aseptic 
precautions subarachanoid block was performed at level of L3-L4 
through a midline approach using 25G Quincke spinal needle and 
study drug was injected with operative table kept flat. The patients 
were made to lie supine immediately and the time of injection of study 
drug was noted. 
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In the perioperative period the following parameters were studied. 
 
 Onset of sensory blockade and motor blockade.  
 Maximum level of sensory blockade and time taken for the 
same.  
 Maximum level of motor blockade and time taken for the same.  
 Two segments sensory regression time.  
 Total duration of analgesia.  
 Total duration of sensory blockade and motor blockade. 
Sensory blockade was tested using pinprick method with a blunt 
tipped 27G needle at every minute for first 5 mins and every 5 mins 
for next 15 mins and every 10 mins for next 30 mins and every 15 
mins till the end of surgery and there after every 30 mins until 
sensory block was resolved.  
 Quality of motor blockade was assessed by Bromage scale.  
 Level of sedation was noted.  
 Side effects if any were noted.  
Haemodynamic monitoring was done during the block every 5 mins 
for first 15 mins and every 10 mins for next 30 mins and once in 15 
mins till the end of surgery and post operatively every hourly 
employing multi parameter monitor which displays heart rate (HR), 
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systolic blood pressure (SBP) diastolic blood pressure (DBP), mean 
arterial pressure (MAP), ECG and SpO2. 
Onset of sensory blockade: was defined as time taken from 
theinjection of study drug till loss of pin prick sensation at T10 level. 
Time taken for maximum sensory blockade: was defined as the time 
taken fromthe injection of study drug to the maximum sensory 
blockade attained. 
Onset of motor blockade: was defined as the time taken from 
theinjection of study drug till the patient was unable to move hip but 
was able to move knee and ankle. 
Quality of motor blockade was assessed by Bromage scale  
Bromage0 - able to move hip, knee and ankle. 
 
Bromage 1- unable to move hip but able to move knee and ankle. 
Bromage 2 - unable to move hip and knee but able to move ankle. 
 
Bromage 3- unable to move hip, knee and ankle. 
Time taken for maximum motor blockade: was defined as the time 
taken from the injection of study drug to maximum motor blockade 
attained (Bromage 3). 
Duration of two segment sensory regression: was defined as the time 
taken fromthe maximum level of sensory block attained till the 
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sensation has regressed by 2 segments. 
 
Duration of analgesia: was defined as the time taken frominjection of 
study drug till the patient requests for rescue analgesic in the post-
operative period. 
 
Duration of sensory blockade: was defined as the time taken from 
time of injectionof study drugtill the patient feels the sensation at S1 
dermatome. 
Duration of motor blockade: was defined as the time taken from time 
of injection of study drug tillthe patient attains complete motor 
recovery (Bromage 0). 
 
Level of sedation: was assessed using subjective sedation score. 
0 awake, conscious, no sedation to slightly restless 
1 calm and composed 
2 awakens on verbal commands 
3 awakens on gentle tactile stimulation 
4 awakens only on vigorous shaking 
5 unarousable  
 
Hypotension was defined as reduction of systolic blood pressure more 
than 30%below baseline value and was treated with increased rate of 
intravenous fluids and incremental doses of injection ephedrine. 
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Bradycardia was defined as heart rate less than 60/minute and was 
treated withinjection atropine 0.6mg IV. 
 
Adverse effects: Any discomfort like nausea, vomiting, shivering, 
pruritus and adverse events such as hypotension, bradycardia, 
respiratory depression and ECG changes were noted. 
STATISTICAL ANALYSIS 
 
30 patients were selected for each group in our study. The data 
collected was subjected to statistical analysis using Statistical Package 
for Social Sciences (SPSS). Results were expressed as range, mean, 
and standard deviations.The comparison of normally distributed 
continuous variables between the groups was performed using one-
way analysis of variance (ANOVA). Nominal categorical data between 
study groups were compared using the chi-square test or Fisher’s exact 
test. Ordinal categorical variables and non-normal distribution 
continuous variables were compared using the Mann-Whitney U-test. 
‘P’ value < 0.05 was considered to be significant. 
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 OBSERVATION AND RESULTS 
 
 
 
All 90 patients completed the study without any exclusion. Inter group 
analysis was done and the collected data was analysed by chi square test. 
Results were obtained in the form of range, mean and standard deviation. 
The probability value ‘p’ of less than 0.05 considered statistically 
significant. 
 
Table 1: Age distribution 
 
AGE IN 
YEARS 
GROUP B GROUP C GROUP D 
NO % NO % NO % 
21-30 16 53.3 14 46.7 18 60.0 
31-40 9 30.0 6 20.0 2 6.7 
41-50 5 16.7 6 20 8 26.7 
51-60 0 0 4 13.3 2 6.7 
TOTAL 30 100 30 100 30 100 
RANGE 20-50 20-59 20-55 
MEAN 31.17 36.60 33.07 
SD 9.752 11.082 11.585 
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Graph 1: Age distribution 
 
 
 
 
 
 
 
 
 
 
Table 1 shows the age distribution of the patients in all the three 
groups. The minimum age in group B (control group), group C 
(clonidine group) and group D (dexmedetomidine group) were 20 
years. The maximum age in group B is 50 years, in group C is 59 years 
and in group D is 55 years. The mean age in group B is 31.17 ± 9.75 
years, group C is 36.6 ± 11.08 years and group D is 33.07 ± 11.58 
years. There is no significant difference in the age of patients between 
the groups. All the three groups were similar with respect to age 
distribution (p>0.05). 
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Table 2: Sex distribution 
 
 
SEX 
NO OF PATIENTS 
GROUP B GROUP C GROUP D 
MALE 15 20 24 
FEMALE 15 10 6 
TOTAL 30 30 30 
 
 
Graph 2: Sex distribution 
 
 
 
 
 
 
 
 
Table 2 shows the sex distribution of the patients in all the three 
groups. There is no significant difference in the sex distribution of the 
patients between the groups. (P>0.05). 
 
59 
 
Table 3: Height distribution 
 
 
Height in 
cm Group B Group C Group D 
n 30 30 30 
RANGE 152-168 150-170 150-170 
MEAN 159.4 161.03 161.6 
SD 4.76 6.18 5.14 
 
 
Graph 3: Height distribution 
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Table 3 shows the height distribution of patients. The mean height in 
group B (control group) is 159.4±4.7cm, group C (clonidine group) is 
161.03± 6.18 cm and group D (dexmedetomidine group) is 
161.6±5.14cm. The minimum height is 152cm in group B, 150cm in 
group C and 150cm in group D. The maximum height was 168 cm in 
group B and 170cm in both the groups D and C. There is no significant 
difference in the height of patients between the groups (p>0.05). 
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Table 4: Body weight distribution 
 
 
Weight In 
Kg Group B Group C Group D 
MEAN 60.9kg 61.33 kg 60.7 kg 
SD 4.62 kg 5.53 kg 5.74 kg 
RANGE 50-68 50-70 50-70 
 
 
 
Graph 4: Body weight distribution 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
62 
 
 
 
Table 4 shows the body weight distribution of patients. The mean body 
weight in group B (control group) is 60.9 ± 4.62 kg, in group C 
(clonidine group) is 61.33 ± 5.53kg and in group D (dexmedetomidine 
group) is 60.7±5.74 kg. The minimum body weight in the groups were 
50kg. The maximum body weight in the group B was 68 kg and in 
group C and group D were 70kg. There is no significant difference in 
the body weight of patients between the groups (p>0.05). 
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Table 5: Mean time taken for sensory onset in minutes 
 
 
Time 
takenfor 
sensoryonse
t in mins 
RANGE MEAN SD 
P 
value 
B vs 
C 
P 
value 
B vs D 
P 
value 
C vs 
D 
Group B 2-4 2.80 0.664 
0.000 0.000 0.024 Group C 1-2 1.43 0.504 
Group D 1-2 1.17 0.379 
 
 
 
 
Graph 5: Mean time taken for sensory onset in minutes 
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The mean time of onset of sensory blockade in group B (control group) is 
2.8±0.66 mins, in group C (clonidine group) is 1.4±0.5mins and in group 
D (dexmedetomidine group) is 1.17±0.37mins. There is a statistically 
highly significant difference when group B was compared with group C 
and with group D (p=0.000) and there is statistically significant 
difference between group C and group D (p=0.024). However there is no 
clinical significance between group C and group D regarding mean time 
taken for onset of sensory blockade. 
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Table 6: Maximum level of sensory block attained 
 
 
Maximumlevel 
ofsensory 
blockattained 
No of patients 
Total 
T4 T5 T6 
Group B 2 4 24 30 
Group C 8 5 17 30 
Group D 12 2 16 30 
 
Graph 6: Maximum level of sensory blockade attained 
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Two out of 30 patients in group B (control group), 8 out of 30 patients in 
group C (clonidine group) and 12 out of 30 patients in group D 
(dexmedetomidinegroup) had T4 level of sensory blockade. 
 
Four out of 30 patients in group B, 5 out of 30 patients in group C and 2 out 
of 30 patients in group D had T5 level of sensory blockade. 
 
Twenty-four out of 30 patients in group B, 17 out of 30 patients in group C 
and 16 out of 30 patients in group D had T6 level of sensory blockade. 
 
There is no statistically significant difference between the groups (p=0.24). 
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Table 7: Mean time taken for maximum sensory blockade in minutes 
 
 
 
 
 
Graph 7: Mean time taken for maximum sensory blockade in minutes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Time 
takenfor 
maximum 
sensory 
block in 
mins 
RANGE MEAN SD P value B vs C 
P value 
B vs D 
P value 
C vs D 
Group B 6-9 7.4 1.102 
0.000 0.000 0.001 Group C 5-7 5.9 0.803 
Group D 4-7 5.2 0.714 
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The mean time taken for attaining the maximum sensory blockade is 
7.4±1.10mins in group B (control group), 5.90±0.80mins in group C 
(clonidinegroup) and in group D (dexmedetomidine group) is 
5.20±0.7mins . There is a statistically highly significant difference when 
group B compared with group C and with group D (p=0.000) and there is 
a statistically significant difference between group C and group D 
(p=0.001). However there is no clinical significant difference between 
group C and group D regarding the mean time taken for attaining the 
maximum sensory blockade. 
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Table 8 : Mean time taken for regression of sensory block by two 
segments 
 
 
 
 
Graph 8 : Mean time taken for regression of sensory block by two  
segments 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Groups 
 
Time 
takenfor 
two 
segment 
sensory 
regression 
in mins 
RANGE MEAN SD P value B vs C 
P value 
B vs D 
P value 
C vs D 
Group B 60-95 79.46 10.16 
0.000 0.000 1.000 Group C 120-155 136.33 10.90 
Group D 120-150 136.33 11.59 
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The mean time taken for regression of sensory block by two segments is 
79.46±10.16mins in group B (control group),136.33±10.9 mins in group 
C(clonidine group). and 136.33±10.9 mins in group D (dexmedetomidine 
group) There is a statistically highly significant difference between group 
B and group C and between group B and group D (p=0.000). There is 
statistically no significant difference between group C and group D 
(p=1.000). 
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Table 9: Mean duration of analgesia 
 
 
 
Duration 
of 
analgesia 
in mins 
RANGE MEAN SD 
P 
value 
B vs C 
P value 
B vs D 
P 
value 
C vs D 
Group B 150-240 191 22.94 
0.000 0.000 0.001 Group C 300-390 342.33 28.12 
Group D 300-420 369.33 34.13 
 
 
 
Graph 9: Mean duration of analgesia 
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The mean duration of analgesia is 191±22.94 mins in group B 
(controlgroup), 342.33±28.12 mins in group C (clonidine group) 
369.33±34.13 mins in group D (dexmedetomidine group). There is a 
statistically highly significant difference between group B and group C 
(p=0.000) and between group B and group D (p=0.000) and between 
group C and group D (p=0.001). However there is no clinical significant 
difference between group C and group D. 
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Table 10: Mean duration of sensory regression to S1 
 
 
 
Duration 
of 
sensory 
regin 
mins 
RANGE MEAN SD 
P 
value 
B vs C
P value 
B vs D 
P 
value 
C vs D 
Group B 170-280 203.33 42.41 
0.000 0.000 0.000 Group C 320-410 365 24.60 
Group D 335-445 396.16 30.61 
 
 
Graph 10: Mean duration of sensory regression to S1 
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The mean duration of sensory regression to S1 is 203.33±42.41 mins 
ingroup  B  (control  group),  365±24.60  mins  in  group  C  (clonidine  
group)396.16±30.61 mins in group D (dexmedetomidine group). There 
is a statistically highly significant difference between group B and group 
C and between group B and group D and between group C and group D 
(p=0.000). However there is no clinical significant difference between 
group C and group D regarding the mean duration of sensory regression 
to S1 
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Table 11: Time taken for onset of motor blockade 
 
 
 
Time 
takenfor 
motoronse
t in mins 
RANGE MEAN SD 
P 
value 
B vs C
P value 
B vs D 
P 
value 
C vs D 
Group B 3-5 4 0.695 
0.000 0.000 0.000 Group C 1-2 1.63 0.49 
Group D 1-2 1.13 0.346 
 
 
 
 
Table 12: Time taken for maximum motor   blockade 
 
 
Time 
TakenFo
r 
maximu
m motor 
block In 
Mins 
RANGE MEAN SD 
P 
value 
B vs C
P value 
B vs D 
P 
value 
C vs D 
Group B 5-9 6.57 0.935 
0.000 0.000 0.000 Group C 5-8 6.43 1.04 
Group D 4-7 5.2 0.887 
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  Graph 11: Motor characteristics 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The mean time taken for the onset of motor blockade is 4.00±0.69mins 
ingroup B (control group), 1.63±0.49mins in group C (clonidine group) 
and ingroup D (dexmedetomidine group) is 1.13±0.346mins. There is a 
statistically highly significant difference between group B and group C 
and between group B and group D and between group C and group D. 
(p=0.000). However there is no clinical significant difference between 
group C and group D. 
The quality of motor blockade is similar in all the groups (Bromage 
grade3). 
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The mean time taken for attaining maximum motor blockade is 
6.57±0.93mins in control group, 6.43±1.045mins in clonidine group and 
5.20±0.887mins in dexmedetomidine group. There is a statistically highly 
significant difference between group B and group C and between group B 
and group D and between group C and group D (p=0.000). 
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  Table 13: Mean duration of motor blockade 
 
  
 
 
 
 
 
            Graph 12: Mean duration of motor blockade 
 
Duration 
of motor 
block In 
Mins 
RANGE MEAN SD 
P 
value 
B vs C
P value 
B vs D 
P 
value 
C vs D 
Group B 135-210 166.16 20.95 
0.000 0.000 0.003 Group C 240-330 279 24.68 
Group D 240-360 303.66 35.95 
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The mean duration of motor blockade is 166.16±20.95mins in group 
B(control  group),  279±24.68  mins  in  group  C  (clonidine  group).  
And303.66±35.95mins in group D (dexmedetomidine group) There is a 
statistically highly significant difference between group B and group C 
(p=0.000) and between group B and group D (p=0.000). However there is 
no clinical significant difference between group C and group D. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
80 
 
    Table 14: Mean heart rate in bpm at various intervals 
  
HR in 
min Group B Group C Group D 
P 
Value 
B vs C 
PValue 
B vs D 
P 
Value 
C vs D 
Basal 84.53± 6.32 86.00±12.3 89.73±17.27 0.563 0.126 0.339 
0min 89.53±6.31 89.03±11.82 94.83±16.65 0.839 0.109 0.125 
2min 83.06±5.35 89.66±14.74 88.90±18.48 0.286 0.100 0.860 
5min 81.53±6.61 86.50±18.19 78.96±17.39 0.164 0.44 0.107 
10min 78.06±5.59 81.66±19.47 74.40±13.88 0.330 0.184 0.101 
20min 76.73±4.50 79.76±14.01 75.40±11.47 0.270 0.550 0.192 
30min 77.46±4.57 76.80±14.65 75.23±9.24 0.814 0.240 0.622 
40min 78.53±4.75 76.93±12.68 76.56±9.48 0.520 0.313 0.900 
50min 78.46±3.18 78.76±9.35 78.33±11.52 0.860 0.950 0.874 
60min 80.90±4.85 79.93±9.39 78.63±11.86 0.125 0.470 0.640 
70min 79.26±4.96 78.76±9.26 80.70±11.59 0.560 0.180 0.478 
80min 79.66±5.737 77.96±9.89 80.06±11.16 0.535 0.143 0.444 
90min 81.06±5.08 79.26±10.45 78.70±9.84 0.304 0.420 0.830 
 
Graph 13: Mean heart rate at various interval in bpm 
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In the group B (control group) the basal value of mean heart rate is 
84.53±6.32 bpm and we observed a decrease in mean heart rate which 
is maximum of 7.80 bpm from basal value at 20th min (9.32% decrease 
from basal value) 
 
In the group C (clonidine group) the basal value of mean heart rate is 86 
± 12.34 bpm and we observed a decrease in mean heart rate which is 
maximum of 9.26 bpm from basal value at 30th min (10.68% decrease 
from basal value). 
 
 
In the group D (dexmedetomidine group) the basal value of mean heart 
rate is 89.73 ± 17.27 bpm and we observed a decrease in mean heart 
rate which is maximum of 15.33 bpm from basal value at 10th min 
(17.08% decrease from basal value). 
 
The mean heart rate from basal to 90th minute recording is statistically 
not significant between the groups 
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Table 15: Mean SBP at various time intervals in mm Hg 
 
SBP in 
min 
   
P 
Value 
B vs 
C 
P 
Value 
B vs 
D 
P 
Value 
C vs 
D 
Group B Group C Group D 
   
    
Basal 127.40±5.308 128.13±7.82 126.00±8.48 0.673 0.447 0.316 
0min 122.80±5.18 125.60±9.83 124.86±10.30 0.173 0.330 0.779 
2min 118.20±5.88 120.73±9.05 114.30±17.84 0.204 0.485 0.748 
5min 112.40±4.76 116.53±8.64 112.33±11.46 0.025 0.977 0.114 
10min 110.73±5.023 113.46±8.05 109.86±10.14 0.120 0.676 0.133 
20min 112.70±5.22 112.13±11.63 107.33±11.09 0.809 0.020 0.107 
30min 115.46±6.078 111.20±12.60 108.00±10.66 0.100 0.002 0.293 
40min 117.20±6.35 110.66±12.63 109.96±9.286 0.014 0.001 0.808 
50min 117.33±6.48 116.400±10.6 110.26±9.780 0.683 0.002 0.024 
60min 120.80±8.49 117.13±9.493 112.60±9.00 0.120 0.001 0.063 
70min 121.46±8.01 116.93±8.30 112.933±8.70 0.036 0.000 0.074 
80min 122.46±7.137 116.00±9.82 112.80±7.76 0.005 0.000 0.167 
90min 123.73±7.73 116.53±9.51 113.40±6.74 0.002 0.000 0.147 
 
Graph 14: Mean SBP at various time intervals in mm Hg 
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In the group B (control group) the basal value of mean SBP is 
127.4±5.3mmHg and we observed a fall in mean SBP which is 
maximum of 16.66 mmHg from mean basal SBP at 10th min (13.08% 
fall from basal SBP).In the group C (clonidine group) the basal value of 
mean SBP is 128.13±7.82mmHg and we observed a fall in mean SBP 
which is maximum of 17.46mmHg from mean basal SBP at 40th min 
(13.63% fall from basal SBP).In the group D (dexmedetomidine group) 
the basal value of mean SBP is 126±8.48mmHg and we observed a fall 
in mean SBP which is maximum of 18.66mmHg from mean basal SBP 
at 20th min (14.81% fall from basal SBP). 
However this is clinically not significant as hypotension is considered as 
a fall in systolic blood pressure more than 30% from basal value or SBP 
less than 90 mmHg. 
The mean SBP from basal to 70th minute recording is statistically not 
significant between group B and group C. The mean SBP from 70th 
to 90th minute recording is statistically highly significant between 
group B and group C. 
The mean SBP from basal to 10th minute recording is statistically not 
significant between group B and group D. The mean SBP from 20th to 
90th minute recording is statistically highly significant between group 
B and group D. 
 
The mean SBP from basal to 90th minute recording is statistically not 
significant between group C and group D. 
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 Table 16: Mean DBP at various time intervals in mm Hg 
 
DBP in 
min 
P 
Value 
B vs C 
P 
Value 
B vs D 
P 
Value 
C vs D 
Group B Group C Group D
Basal 81.80±3.12 84.46±6.51 81.67±9.728 0.048 0.943 0.195 
0min 81.80±3.12 78.53±7.314 78.80±8.19 0.028 0.066 0.895 
2min 80.33±3.11 76.00±5.87 76.26±8.415 0.001 0.016 0.887 
5min 76.80±3.34 72.53±8.06 70.73±10.58 0.010 0.004 0.462 
10min 72.66±2.98 72.00±8.18 68.33±12.36 0.677 0.067 0.181 
20min 70.46±3.98 70.46±6.31 71.66±10.25 10.000 0.553 0.587 
30min 71.60±5.10 70.13±7.62 70.53±9.15 0.385 0.579 0.855 
40min 73.00±6.09 67.86±.576 71.33±8.276 0.016 0.378 0.138 
50min 73.20±5.39 72.33±12.09 71.53±7.13 0.721 0.312 0.756 
60min 73.33±5.73 72.86±10.52 72.66±5.68 0.832 0.653 0.927 
70min 74.40±5.96 73.23±11.90 73.06±6.51 0.627 0.412 0.946 
80min 75.66±4.95 73.63±12.40 71.86±5.940 0.408 0.009 0.485 
90min 75.93±6.180 74.86±13.65 75.50±8.182 0.698 0.818 0.828 
 
Graph 15: Mean DBP at various time intervals in mm Hg 
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In the group B (control group) the basal value of mean DBP is 
81.8±3.12mmHg and we observed a fall in mean DBP which is 
maximum of 11.33mmHg from mean basal DBP at 20th min (13.85% 
fall from basal DBP). 
 
In the group C (clonidine group) the basal value of mean DBP is 
84.6±6.51mmHg and we observed a fall in mean DBP which is 
maximum of 16.6mmHg from mean basal DBP at 40th min (19.65% 
fall from basal DBP). 
In the group D (dexmedetomidine group) the basal value of mean DBP 
is 81.6±9.76mmHg and we observed a fall in mean DBP which is 
maximum of 13.3mmHg from mean basal DBP at 10th min (16.32% 
fall from basal DBP). 
The mean DBP from basal to 5th minute recording is statistically not 
significant between group B and group C. The mean DBP from 10th 
minute to 90th minute recording is statistically significant between 
group B and group C. 
 
The mean DBP from 2th minute to 10th minute and from 20th minute to 
90th minute recordingis statistically significant between group B and 
group D. The mean DBP from basal to90th minute recording is 
statistically not significant between group C and group D 
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Table 17: Mean MAP at various intervals in mm Hg  
P 
Value 
B vsC 
 
P 
Value 
B vs D 
 
P 
Value 
C vs D 
MAP in Group B Group C Group D
min 
Basal 96.13±6.47 96.53±8.43 96.03±9.05 0.838 0.961 0.826 
0min 93.96±4.97 94.89±6.37 94.26±8.32 0.946 0.866 0.917 
2min 89.93±4.96 90.06±6.38 89.50±8.49 0.928 0.810 0.771 
5min 85.46±4.52 87.36±7.76 84.23±10.50 0.251 0.559 0.196 
10min 83.93±4.60 85.10±7.70 81.06±12.40 0.479 0.240 0.136 
20min 84.40±4.87 84.56±6.11 82.53±10.45 0.908 0.379 0.362 
30min 86.53±3.94 83.96±6.93 82.80±8.762 0.083 0.038 0.570 
40min 87.40±5.15 84.93±11.0 84.50±8.02 0.274 0.101 0.863 
50min 88.43±4.86 85.80±9.46 85.26±7.36 0.180 0.054 0.808 
60min 89.73±5.53 86.46±8.43 85.30±06.22 0.081 0.005 0.544 
70min 90.96±4.97 85.60±7.06 86.26±6.564 0.001 0.003 0.706 
80min 91.60±5.462 85.67±8.84 86.16±5.123 0.003 0.000 0.808 
90min 92.76±5.41 85.63±8.97 86.80±5.162 0.000 0.000 0.540 
 
Graph 16: Mean MAP at various intervals in mm Hg 
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In the group B (control group) the basal value of mean MAP is 
96.3±6.47 mmHg and we observed a fall in mean MAP which is 
maximum of 12.2mmHg from mean basal MAP at 10th min (12.69% 
fall from basal MAP). In the group C (clonidine group) the basal 
value of mean MAP is 96.53±8.43 mmHg and we observed a fall in 
mean MAP which is maximum of 12.56 mmHg from mean basal 
MAP at 30th min (13.01% fall from basal MAP). 
 
In the group D (dexmedetomidine group) the basal value of mean 
MAP is 96.03±9.05 mmHg and we observed a fall in mean MAP 
which is maximum of 14.96 mmHg from mean basal MAP at 30th 
min (15.58% fall from basal MAP). 
 
The mean MAP from basal to 60th minute recording is statistically 
not significant between group B and group C. The mean MAP from 
70th to 90th minute recording is statistically highly significant 
between group B and group C. 
 
The mean MAP from basal to 50th minute recording is statistically 
not significant between group B and group D. The mean MAP from 
60th to 90th minute recording is statistically highly significant 
between group B and group D. 
 
The mean MAP from basal to 90th minute recording is statistically 
not significant between group C and group D. 
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Graph 17: Mean sedation scores 
 
 
 
 
 
 
 
 
 
 
The  mean  sedation  score  is  0.4±0.49  in  group  B  (control 
group), 0.50±0.682 in group C (clonidine group), 0.53±0.681 in 
group D (dexmedetomidine group). There is a statistically highly 
significant difference between group B and group C and between 
group B and group D (p=0.000). There is statistically no significant 
difference between group C and group D (p=0.850).
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               Graph 18: Hypotension and bradycardia 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In group B (control group) two out of thirty patients, in group C 
(clonidine group) seven out of thirty patients and in group D 
(dexmedetomidine group) seven out of thirty patients developed 
hypotension, which is statistically not significant (p>0.05). All the 
patients who developed hypotension could be easily treated with 
intravenous fluids and vasopressor. 
 
In group B (control group) one out of thirty patients, in group C 
(clonidine group), four out of thirty patientsand in group D 
(dexmedetomidine group) five out of thirty patients developed 
bradycardia, which is statistically not significant (p>0.05). All the 
patients who developed bradycardia were treated by single dose of 
0.6 mg of atropine. 
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         DISCUSSION 
 
 
 
Subarachnoid block with bupivacaine has been most extensively used 
for lower limb surgeries today. It has the definitive advantage of profound 
nerve block produced in a large part of the body by the relatively simple 
injection. Commonly used local anaesthetics for intrathecal anaesthesia are 
lignocaine and bupivacaine. Bupivacaine 0.5% heavy has more prolonged 
action compared to lignocaine.However, a single intrathecal injection of 
bupivacaine alone provides analgesia for only 2 – 2.5 hours. Other method of 
prolonging anaesthesia is using a continuous epidural analgesia, which is 
technically more difficult and more expensive. To overcome this, various 
adjuvants have been tried and used successfully. 
Hence, an intrathecal additive to these local anaesthetics forms a reliable 
and reproducible method of prolongedduration of anaesthesia and also to 
provide post-operative analgesia. This technique being simple and less 
cumbersome has gained a wide acceptance worldwide.A number of adjuvants 
to local anesthetics for spinal anaesthesia like opioids (fentanyl and 
buprenorphine), benzodiazepines (midazolam), ketamine and neostigmine 
have been used. The most common agents used are opioids and they have 
formed a cornerstone option for the treatment of post-operative pain.43 
Spinal opiates prolong the duration of analgesia, but they do have 
drawbacks of late and unpredictable respiratory depression, pruritus, nausea, 
vomiting and urinary retention.40,44,45 which requires constant postoperative 
monitoring and urinary catheterisation. Hence opioids are not ideally suited 
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for all patients and for ambulant surgeries. 
Intrathecal alpha 2 agonists are found to have antinociceptive action for 
both somatic and visceral pain.9 So in this context alpha 2 agonists may be a 
very useful drug along with the local anesthetic0.5% hyperbaricbupivacaine 
for spinal anaesthesia.43 
Ninety patients of ASA Grade-I and Grade-II posted for elective lower 
limb surgeries were selected randomly into 3 groups (n=30). Randomization 
was done using simple sealed envelope technique.  
 
Demographic data: demographic data comparing age, sex, height, weight 
showsno statistical difference among the groups. 
Hypothesis done before the study: It was hypothesised that both clonidine 
anddexmedetomidine prolongs the duration of postoperative analgesia 
compared to the control. There will be no difference regarding the duration of 
analgesia between clonidine and dexmedetomidine as equipotent doses are 
used. 
Dosages of drugs selected 
 
In our study 50 μg of clonidine and 5 μg of dexmedetomidine were 
used.Asano T et al47 showed that binding affinity to spinal alpha-2 receptors 
of dexmedetomidine compared with clonidine is approximately 1:10. In a 
study conducted by Kanazi GE et al31the doses of dexmedetomidine and 
clonidine used was 3μg and 30μg respectively.  
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In a study conducted by Sarma et al48 the doses of dexmedetomidine and 
clonidine used was 5μg and 50μg respectivelyThe doses of dexmedetomidine 
and clonidine were found to be equipotent in the ratio of 1:10 and would 
produce similar effects on the characteristics of bupivacaine spinal 
anaesthesia.42,43,35,39 Hence in our study we selected 10 times the dose of 
dexmedetomidine as clonidine that is 50 µg. 
Analysis of data between the groups 
 
Sensory block characteristics 
Onset of sensory blockade 
In our study the mean time taken for onset of sensory block is 2.8±0.6 
mins in the control group, 1.43±0.5mins in the clonidine group and 
1.17±0.379mins in the dexmedetomidine group. There is a statistically 
significant decrease in the onset of sensory blockade in clonidine group and 
in the dexmedetomidine group compared to the control group. 
 
In a study conducted by Saxena H et al.37 authors observed the onset of 
sensory blockade to be 6.57±0.49 mins in control group and 2.58±0.33 mins, 
2.54±0.34mins and 2.09±0.89 mins in clonidine group (15 µg, 30 µg and 37.5 
µg respectively) and in this study there was a significant reduction in the 
onset time which concurs with our study. But compared to our study the onset 
time of sensory block is higher and this could be possibly due to the dose of 
clonidine used being less than compared to our study. 
In a study conducted by Al-Mustafa MM et al.36 authors observed the 
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onset of analgesia to be 9.5±3mins in control group and 6.3±2.7 mins and 
4.7±2 mins in dexmedetomidine group (5 µg and 10 µg respectively) and in 
this study there was a significant reduction in the onset time of sensory block 
which is comparable to our study. 
 
In studies conducted by Dobrydnjov I et al.,29Benhamou D et 
al.,27Grandhe RP et al.34 and De Kock M et al.28 in clonidine group and study 
conducted by Shukla D et al41 in dexmedetomidine group, authors observed a 
significant reduction in the onset time of sensory blockade which concurs 
with our study. 
In a study conducted by Kanazi GE et al.31 authors observed the onset of  
sensory block to be 9.7±4.2 mins in control group, 7.6±4.4 mins in clonidine 
group and 8.76± 3.7 mins in dexmedetomidine group, which is more than the 
value in our study and there is no significant reduction in the onset time of 
sensory blockade .This could be due to the less doses of clonidine and 
dexmedetomidine used. 
\\\ 
Time taken for maximum sensory blockade 
The mean time taken for maximum sensory blockade in the present 
study is 7.4±1.1 mins in the control group, 5.9±0.8 mins in the clonidine 
group and 5.2±0.71 mins in dexmedetomidine group. There is a statistically 
significant decrease in the mean time taken for the maximum sensory 
blockade in the clonidine group and dexmedetomidine group compared to the 
control group. 
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In a study conducted by Saxena H et al.37 authors observed the mean 
time to achieve maximum sensory level in control group was 7.3±1.25mins 
which almost concurs with our study in the control group and 6.8±1.20 mins, 
7.4±1.31 mins and 6.7±1.12mins in clonidine groups (15µg, 30µg, 37.5µg 
respectively)which is more than our study in clonidine group and this may be 
due to less dose of clonidine used in their study. 
Our study is comparable with the study conducted by Shukla D et al41 
who also observed a significant decrease in the meantime taken for the 
maximum sensory blockade in the dexmedetomidine group. 
 
Maximum level of sensory blockade achieved 
 
In our study the maximum level of sensory blockade achieved is T4. 
Two out of 30 patients in control group, 8 out of 30 patients in clonidine 
group and 12 out of 30 patients in dexmedetomidinegroup had T4 level of 
sensory blockade. There is no statistical significant difference in the 
maximum level of sensory blockade in the clonidine group and 
dexmedetomidine group compared to the control group. 
In a study conducted by Kanazi GE et al.,31the median and range of the 
peak sensory level reached were T6 in group B(control group), T6.5 in group 
C(clonidine group) and T6in group D(dexmedetomidine group) without 
significant differences between the groups.  
In studies conducted by Al-Ghanem SM  et al.,35Gupta R et al.,38 Gupta 
R et al.40 and Eid HEA et al.39 with dexmedetomidine and study conducted by 
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Strebel S et al.30 with clonidine there was no statistically significant 
difference in the maximum level of sensory blockade which also concurs with 
our study. 
 
The time taken for regression of sensory block by two segments 
 
The time taken for regression of sensory block by two segments in the 
present study is 79.46±10.1 mins in the control group, 136.33±10.90 mins in 
the clonidine group and 136.33±11.590 mins in dexmedetomidine group. 
There is a statistically significant increase in the mean time taken for 
regression of sensory block by two segments in clonidine group and 
dexmedetomidine group compared to the control group. 
In a study conducted by Kanazi GE et al.31 authors observed the time 
taken for regression of sensory block by two segments to be 80±28 mins in 
control group, 101±37 mins in clonidine group and 122±37 mins in 
dexmedetomidine group, where they also found a significant prolongation of 
two segment regression compared to the control group which compares with 
our study. 
 
Our study is also consistent with studies done by Dobrydnjov I et 
al.,29Saxena H et al.,37Sethi BS et al.33 in clonidine group and studies done by 
Gupta R et al.40 and Eid HEA et al.39 in dexmedetomidine group. Here 
authors observed a statistically significant increase in the mean time taken for 
regression of sensory block by two segments. 
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The time taken for sensory block to regress to S1 
 
The time taken for sensory block to regress to S1 in the present study is 
203.33±42.41 mins in the control group, 365.0±24.6 mins in the clonidine 
group and 396.16±30.61 mins in the dexmedetomidine group. There is a 
statistically significant increase in the mean time taken for regression of 
sensory block to S1 in clonidine group and dexmedetomidine group 
compared to the control group. 
 
This compares with the study conducted by Kanazi GE et al.31 where the 
time taken for regression of sensory block to S1 to be 190±48 mins in control 
group, 272.±38 mins in clonidine group and 303±75 mins in in 
dexmedetomidine group which is less than the value in our study. This could 
be due to the less doses of clonidine and dexmedetomidine used in their 
study. 
 
In  studies conducted by Al-Ghanem SM et al.68 Al-Mustafa MM  et al.69 
 
Gupta R et al.,40 Gupta R et al,38 Eid HEA et al.39 and Shukla D et al.41 
authors observed a statistically significant increase in the mean time taken for 
regression of sensory block to S1 dermatome in dexmedetomidine group 
which concurs with our study. 
Duration of analgesia 
 
The mean duration of analgesia in our study is 191±22.9 mins in control 
group,342.33±28.12 mins in clonidine group and 369.33±34.13 mins in 
dexmedetomidine group. There is a statistically highly significant increase in 
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the duration of analgesia in dexmedetomidine and clonidine group compared 
to the control group. 
 
Our study concurs with the study conducted by Grandhe RP et al.,34 
where authors observed the mean duration of analgesia of 3.8 ±0.7 hours in 
the control group and 6.3±0.8 hours when using clonidine of 1µg/kg with a 
mean weight of 60.6±19.4 kg. 
 
In studies conducted by Dobrydnjov I et al.29 and Benhamou D et al.27 in 
the clonidine group the duration of analgesia was 247±75 mins , 153 ± 80 
mins respectively. StrebelS et al30et  andSaxena H at al37showed that duration 
of analgesia with Clonidine Groupwas proportional to its dose.In studies 
conducted by Gupta R et al.,38 Gupta R et al.40in dexmedetomidine group the 
duration of analgesia was 478.4±20.9 min and 251.7 ± 30.69 resectively, Eid 
HEA et at al39showed that duration of analgesia with dexmedetomidine 
Groupwas proportional to its dose.They also observed a statistically 
significant increase in the mean duration of analgesia. 
 
Motor block characteristics 
 
Onset of motor blockade 
 
In our study the mean time for onset of motor block is 4 ±0.69 mins in 
control group, 1.63±0.49 mins in clonidine group and 1.13±0.346 mins 
indexmedetomidine group. There is a statistically highly significant decrease 
in the mean time for onset of motor blockade in the dexmedetomidine group 
and clonidine group compared to the control group. 
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In studies conducted byKanazi GE et al 31.,Al-Mustafa MM  et 
al.,36Gupta R et al.40 and Shukla D et al.41 in the dexmedetomidine group and 
studies done by Saxena H et al.37 and De Kock M et al.28 in the clonidine 
group authors observed a significant decrease in the mean time for onset of 
motor blockade which correlates with our study. 
 
Time taken for maximum motor blockade and grade of motor blockade 
 
The mean time taken for maximum motor blockade in our study is 
6.57±0.9 mins in control group, 6.43±1.04 mins in clonidine group and 
5.20±0.88 mins in dexmedetomidine group. There is a statistically significant 
decrease in the time taken for maximum motor blockade in dexmedetomidine 
and clonidine group compared to the control group. But the grade of motor 
blockade in the study groups did not differ. All the groups had a motor 
blockade of Bromage grade 3. 
In a study conducted by Kanazi GE et al.,31the time taken for maximum 
motor block was significantly shorter in dexmedetomidine group(13.2±5.6 
min) and clonidine group (11.7±5.9 min) than in control group(20.7±10.3 
min). There was no significant difference between dexmedetomidine and 
clonidine group 
This concurs with study conducted by Al-Mustafa MM et al.36 and 
Shukla D et al.41 where the time taken for maximum motor blockade is 
significantly shorter in dexmedetomidine group compared to the control 
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group. 
This is also consistent with the studies done by Sethi BS et al.33 and 
Saxena H et al.37 who observed the complete motor blockade of the lower 
extremity in all patients in clonidine group. 
In study conducted by Dobrydnjov I et al.29 authors found a better 
quality of block in all the three clonidine groups, where no supplementation 
with general anaesthesia for relaxation request from surgeons was needed 
intraoperatively. 
 
Duration of motor blockade 
 
In our study the mean duration of motor blockade was 166.16±20.95 
mins in control group, 279±24.68 mins in clonidine group and 303.66±35.95 
mins in dexmedetomidine group. There is a statistically highly significant 
increase in the duration of motor blockade in dexmedetomidine group and 
clonidine group compared to the control group. 
 
This compares with study conducted by Kanazi GE et al.31 where the 
mean duration of motor blockade is 163±47 mins in control group, 216±35 
mins in clonidine group and 250±76 mins in dexmedetomidine group which 
is less than the value in our study. This could be due to the less doses of 
clonidine and dexmedetomidine used. Our study almost concurs with the 
study conducted by Kaabachi O et al.32 who observed the mean duration of 
motor blockade to be 252±79mins when using clonidine of 1µg/kg. 
 
Our study also correlates with studies conducted by Al-Mustafa MM et 
al.,36Al-Ghanem SM et al.,35 Gupta R et al.,40 Gupta R et al.,38 Eid HEA et 
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al.39 and Shukla D et al.41 in dexmedetomidine group and in studies conducted 
by Saxena H et al.,37Strebel S et al.,30Dobrydnjov I et al.,29Sethi BS et 
al.,33Grandhe RP et al.34 and Benhamou D et al.27 in the clonidine group, here 
authors observed a significant increase in the duration of motor blockade. 
 
Hemodynamics 
Systolic Blood Pressure 
 
In the control group we observed a maximum fall in mean systolic blood 
pressure of 16.66 mmHg from mean basal systolic blood pressure at 10th min, 
in the clonidine group it was 17.46mmHg at 40th min and in the 
dexmedetomidine group it was 18.66mmHg at 20th min. 
There was no statistically significant difference in any of the three 
groups. However it was found that there was a delay in maximum fall in 
systolic blood pressure in the clonidine group compared to the 
dexmedetomidine group and the control group. 
 
Diastolic Blood Pressure 
 
In the control group we observed a maximum fall in mean diastolic 
blood pressure of 11.33mmHg from mean basal diastolic blood pressure at 
20th min, in the clonidine group it was 16.6 mmHg at 40th min and in the 
dexmedetomidine group it was 13.3 mmHg at 10th min. 
There was no statistically significant difference in any of the three 
groups. However it was found that there was a delay in maximum fall in 
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diastolic blood pressure in the clonidine group compared to the 
dexmedetomidine group and the control group. 
 
Mean Arterial Blood Pressure 
In the control group we observed amaximum fall in mean arterial 
pressure of 12.2 mmHg from mean basal MAP at 10th min, in the clonidine 
group it was 12.56 mmHg at 30th min and in the dexmedetomidine group it 
was 14.96 mmHg at 30th min.  
There was no statistically significant difference in any of the three 
groups regarding fall in MAP. However it was found that there was a delay in 
maximum fall in MAP in the clonidine group and the dexmedetomidine 
group compared to the control group. 
In a study conducted by Sethi BS et al.33authors observed lowest mean 
mean arterial pressure (70 mmHg) in clonidine group (1 µg/kg, mean weight 
57.93±4.75 kg) which is less than that in our study (76.05±2.54 mmHg). 
 
In a study conducted by Strebel S et al.30 the maximum decrease in mean 
arterial pressure was 25%±14%, 26%±12% and 25±13%, who received 
clonidine 37.5 µg, 75 µg and 150 µg respectively. 
 
In a study conducted by Grandhe RP et al.34 the incidence of 
hypotension (fall in mean arterial pressure of>20% of pre-induction value) 
was 10/15 patients in clonidine group (clonidine 1 µg/kg, mean weight 
60.6±19.4 kg) and 8/15 patient in clonidine group (clonidine 1.5 µg/kg, mean 
weight 62.7±18 kg). 
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In a study conducted by Al-Ghanem SM et al.35 authors observed that 
the hypotension (fall in mean arterial pressure of>30% of pre-induction 
value) was mild to moderate in both dexmedetomidine and fentanyl group. 
4/38 patients in dexmedetomidine group and 9/38 patient in fentanyl group 
had hypotension but it did not reach a significant difference. 
Heart Rate  
In the control group we observed a maximum decrease in the mean heart 
rate of 7.8 bpm from basal value at 20th min, in the clonidine group it was 
9.26 bpm at 30th min and in the dexmedetomidine group it was 15.33 bpm at 
10th min.There was no statistically significant difference in any of the three 
groups regarding decrease in the mean heart rate.Five patients in 
dexmedetomidine group, four patients in clonidine group and one patient in 
control group had bradycardia which was not statistically 
significant.Bradycardia was easily reversed with 0.6mg intravenous atropine 
in all the patients. 
 
In a study conducted by Kaabachi O et al.32 the authors observed the 
incidence of bradycardia to be 30% in clonidine (2 µg/kg) group which is 
higher compared to our study and this may probably due to larger dose of 
clonidine (2µg/kg) used compared to our study (17.77%). 
 
Our study is consistent with the studies done by Kanazi GE et al.,31Al-
Ghanem SM et al.35 and Al-Mustafa MM et al.36 who observed that there was 
no significant difference in mean value of heart rate throughout the 
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intraoperative and postoperative period. 
Adverse effects 
Sedation 
In our study, sedation is assessed using a subjective sedation scale at the 
end of surgery.In our study, in the dexmedetomidine group 10% of patients 
had grade 2 sedation, 33.33% had grade 1 sedation and remaining 56.7% had 
grade 0 sedation and in the clonidine group 36% of patients had grade 2 
sedation, 30% had grade 1 sedation and remaining 60% had grade 0 sedation 
compared to 40% of patients in control group having grade 1 sedation and 
60% having grade 0 sedation. No patients in control group had grade 2 
sedation and there was a statistical significance in mean sedation scores 
between control group and clonidine group and between control group and 
dexmedetomidine group. There was no statistical significance between 
clonidine group and dexmedetomidine group. 
 
In a study conducted by Saxena H et al.37 higher incidence of sedation 
was seen in the clonidine group (37.5 µg) compared to our study. The authors 
found 90% of the patients were asleep but arousable in the clonidine group 
(37.5µg).However in a study conducted by Gupta R et al.40 there was 
significant difference in mean sedation scores among the groups. 
In a study conducted by Strebel S et al.,30 Al-Ghanem SM et al.35 and 
Al-Mustafa MM et al.36 there was no significant difference in mean sedation 
scores among the groups. 
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Hypotension 
Two patients in control group, seven patients in clonidine group and 
seven patients in dexmedetomidine group developed hypotension and were 
easily managed with intravenous fluids and vasopressor. 
Our study is comparable with the studies done by  Sethi BS et 
al.33Strebel S et al.30Grandhe RP et al.34  Al-Ghanem SM et al.35 in which 
patients had hypotension but there was no significant difference throughout 
the intraoperative and postoperative period. 
Bradycardia 
Five patients in dexmedetomidine group, four patients in clonidine group 
and one patient in control group had bradycardia which was not statistically 
significant.Bradycardia was easily reversed with 0.6mg intravenous atropine 
in all the patients. 
Our study is consistent with the studies done by Kanazi GE et al.,31 
 
Al-Ghanem SM et al.35 and Al-Mustafa MM et al.36 who observed that there 
was no significant difference in mean value of heart rate throughout the 
intraoperative and postoperative period. 
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SUMMARY 
  
 
 
 
The present study entitled “a comparative study of intrathecal 
dexmedetomidine and clonidine as an adjuvant to intrathecal bupivacaine in 
elective lower limb surgeries” was undertaken to evaluate the efficacy and the 
safety of dexmedetomidine and clonidine as adjuvant to intrathecal 
hyperbaric 0.5% bupivacaine. 
 
Ninety patients were randomly divided into three groups, each group 
consisting of thirty patients (n=30): 
 
Group B (control group): received 15mg of 0.5% hyperbaric bupivacaine 
with0.5 ml normal saline. 
Group C (clonidine group): received 15 mg of 0.5% hyperbaric 
bupivacainewith 50 µg clonidine. 
Group D (dexmedetomidine group): received 15mg of 0.5% 
hyperbaricbupivacaine with 5µg dexmedetomidine. 
 
All patients in the age group 20 to 60 years, of either sex belonging to 
ASA class I and II posted for elective lower limb surgeries under spinal 
anaesthesia were included in the study. The onset, maximum level, duration 
of sensory blockade and motor blockade andhaemodynamic parameters were 
studied 
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Results obtained in our study 
 
 The time taken for onset of sensory blockade in group B was 2.8±0.6 
mins, in group C 1.43±0.5 mins and in group D 1.17±0.379 mins. 
 The time taken for maximum sensory blockade in group B was 
7.4±1.1 mins, in group C 5.9±0.8 mins and in group D 5.2±0.71 mins. 
 The time taken for two segment regression of sensory blockade in 
group B was 79.46±10.1 mins, in group C 136.33±10.9 mins and in 
group D 136.33±11.59 mins. 
 The time taken for regression of sensory block to S1 in group B was 
203.33±42.41 mins, in group C 365±24.6 mins and in group D 
396.16±30.6 mins. 
 The duration of analgesia in group B was 191±22.9 mins, in group C 
342.33±28.12 mins and in group D 369.33±34.13 mins. 
 The time taken for onset of  motor blockade in group B was 4±0.69 
mins, in group C 1.63±0.49 mins and in group D 1.13±0.346 mins. 
 The time taken for maximum motor blockade in group B was 
6.57±0.9 mins, in group C 6.43±1.04 mins and in group D 5.2±0.88 
mins. 
 The duration of  motor blockade in group B was 166.16±20.95 mins, 
in group C 279±24.68 mins and in group D 303.66±35.95 mins. 
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It was found that there is an early onset of both sensory and motor 
blockade with prolonged duration of analgesia in dexmedetomidine and 
clonidine group when compared to the control group with minimal side 
effects. Small percentage of patients developed significant fall in blood 
pressure and heart rate which were easily managed without any untoward 
effects. Seven patients each in dexmedetomidine group and clonidine group 
and two patients in control group developed hypotension requiring 
treatment. Five patients in dexmedetomidine group, four patients in 
clonidine group and one patient in control group developed bradycardia 
requiring treatment. 
More number of patients in the dexmedetomidine group and clonidine 
group were sedated and was easily arousable. No patient had any respiratory 
depression, nausea, vomiting or shivering in either of the groups. 
 
In the present study the efficacy of intrathecal dexmedetomidine and 
clonidine were compared and we noticed that there was significantly shorter 
onset of motor and sensory block and a significantly longer sensory and 
motor block than bupivacaine alone.  
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CONCLUSION 
 
 
 
From the present study it can be concluded that the supplementation of 
bupivacaine with dexmedetomidine 5 μg or clonidine 50 μgin spinal 
anaesthesia produces significant shorter onset of motor and sensory block 
with longer duration of sensory and motor block when compared to 
bupivacaine alone. The 50 μg of clonidine or 5 μg dexmedetomidine dose 
provides maximum benefit with minimum side effects. These doses has 
minimal effect on sedation level, heart rate and mean arterial pressure without 
requiring any therapeutic intervention and hence can be advocated as an 
adjuvant to bupivacaine in spinal anaesthesia for lower limb surgeries. 
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     PROFORMA 
 
NAME:                     AGE:                        SEX:    
IP NO: 
HT:                        WT:                                      
DIAGNOSIS:                                                                       
SURGERY:                                                          
ASA Physical Status: 
Co-Morbidity:                                                                                                      
Any drugs: 
GROUP:B/C/D  
SUB ARACHANOID BLOCK: 
Pre- OP:                 
PR:            SBP:                            DBP:                       MAP:          SPO2: 
SENSORY BLOCKADE  
Time of onset (T10): 
Time for maximum sensory blockade and level: 
Time for two dermatome sensory regression: 
Duration of sensory blockade: 
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MOTOR BLOCKADE  
Time of onset (Bromage 1): 
Time for maximum motor blockade (Bromage 3): 
Duration of motor blockade: 
Level of sedation (sedation scale) 
Duration of analgesia: 
HAEMODYNAMICS: 
TIME(MIN) PR SBP DBP MAP SP02 
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SIDE EFFECTS AND COMPLICATIONS:  
Nausea/vomiting: 
Shivering: 
Hypotension (ephedrine required): 
Bradycardia (atropine required): 
